



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 09/424,519

Applicant: Mitchell et al.

Filed: March 3, 2000

TC/AU: 1614

Examiner: Kwon, B. Y. S.

Docket No.: 175931 (DHHS Reference No. E-167-1997/0-US-07)

Customer No.: 45733

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND DECLARATION UNDER 37 C.F.R. § 1.132 OF JAMES B. MITCHELL

I, James B. Mitchell, hereby declare that:

1. I am currently the Branch Chief of the Radiation Oncology Branch at the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. I have held this position since 1992. I have over 30 years of experience in the area of radiation biology, including modulation of cellular redox potential (oxidative stress), radiation sensitizers and protectors, and imaging free radicals. My Curriculum Vitae sets forth further details of my research and educational background (Exhibit A).

2. I received a Bachelor of Science Degree in Chemistry and Biology from Austin Peay State University in Clarksville, Tennessee in 1970, a Master's Degree in Biology from George Peabody College in Nashville, Tennessee in 1975, and a Ph.D. Degree in Cellular Radiation Biology from Colorado State University, Fort Collins, Colorado in 1978.

3. I am one of the named inventors in the present application. I am aware of the application and pending claims.

4. Claim 28 of the application has been rejected for obviousness-type double patenting in view of claim 22 of U.S. Patent 5,462,946 ("the '946 patent") and claim 2 of U.S. Patent 6,605,619 ("the '619 patent").

5. The Office Action argues that since radiation can cause cancer, it must follow that any agent (including Tempol) shown to protect against radiation damage should also result in the delay of onset of tumor formation. In my opinion, this contention is not true.


6. Claim 22 of the '946 patent is directed to a method for treating the effects of oxidative stress due to the production of harmful free radical species in an organism comprising administering a composition comprising Tempol. Claim 2 of the '619 patent recites a method of treating or preventing damage to normal cells, tissue, or organs in a mammal that has been exposed to ionizing radiation comprising administering to the mammal, after exposure to ionizing radiation, a composition comprising Tempol.

7. Cancer is a complex disease. It has been hypothesized that cancer results from an initiation event, followed by a series of complex promotion events (over a long period of time) that ultimately result in tumor formation (Vogelstein B, and Kinzler KW. The multistep nature of cancer. *Trends Genet* 9: 138-141, 1993; Weinberg RA. How cancer arises. *Sci Am* 275: 62-70, 1996). One might consider radiation or oxidation stress as being an "initiation event" (along with many other initiators such as toxic chemicals, air pollutants, UV light, etc.); however, the complex promotion events and mechanisms that occur over long periods of time that ultimately result in tumor formation are not known. Genetic defects, such as due to ataxia telangiectasia and Li-Fraumeni's syndrome, which are inherited conditions, can lead to tumor formation, but the complex promotion events associated with these genetic defects are not known. It is also not known whether the complex promotion events associated with radiation or oxidative stress initiation are the same as those associated with genetic defects. Because there are so many unknown variables in cancer initiation, formation, and termination mechanisms and pathways, starting from a genetic defect, the chances are minimal that one of ordinary skill in the art would have a reasonable expectation of success to arrive at the methods of the present invention. For

example, to arrive at the presently claimed invention, one of ordinary skill in the art should test an untold number of gene mutations and study pathways relating to such mutations leading to cancer. This would entail undue experimentation and hardship.

8. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,


James B. Mitchell, Ph.D. 3-22-06
Date

M:\CLIENTS\WIH\131-132\175931DEC132 - 2.DOC

CURRICULUM VITAE

NAME:

James B. Mitchell

DATE AND PLACE OF BIRTH:

July 2, 1948, Springfield, Tennessee

CITIZENSHIP:

United States

MARITAL STATUS:

Married, 3 Children

EDUCATION:

1966-1970

Austin Peay State University
Clarksville, Tennessee
Chemistry and Biology
Bachelor of Science

1973-1975

George Peabody College
Nashville, Tennessee
Biology
Master of Arts

1975-1978

Colorado State University
Fort Collins, Colorado
Cellular Radiation Biology
Doctor of Philosophy

POSITIONS HELD:

November 1970-May, 1975

Research Associate
Vanderbilt University Hospital
Department of Radiation Therapy
Nashville, Tennessee

June 1975-May, 1979

Research Associate
Colorado State University
Department of Radiology and
Radiation Biology
Fort Collins, Colorado 80521

June 1979-June, 1980

IPA Assignee
Radiobiology Section
Radiation Oncology Branch
National Cancer Institute

	National Institutes of Health Bethesda, MD 20892
June 1980-May, 1984	Cancer Expert Radiobiology Section Radiation Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
June 1984-September, 1993	Head, Radiation Biology Section Radiation Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
September 1987-September 1993	Deputy Branch Chief Radiation Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
February 1992-March 1993	Acting Branch Chief Radiation Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
October 1993-Present	Branch Chief Radiation Biology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
August 1997-July 1999	Acting Branch Chief Radiation Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892
January 1998-Present	Senior Biomedical Research Service National Cancer Institute National Institutes of Health Bethesda, MD 20892
November 2004-Present	Acting Branch Chief Radiation Oncology Branch, NCI

MILITARY SERVICE:

None

PROFESSIONAL SOCIETIES:

Radiation Research Society
American Society for Therapeutic
Radiology and Oncology
American Association for Cancer Research
Society for Free Radical Biology and Medicine
Oxygen Club of Washington, D.C.

HONORS AND OTHER SPECIAL SCIENTIFIC RECOGNITION:

1995	Co-Editor of Book Lung Cancer: Principles and Practice Lippincott-Raven, 1996
1995	National Cancer Institute Equal Employment Opportunity Special Achievement Award
July 1986 - June 1990	Associate Editor - Radiation Research
1990 - Present	Associate Editor - International Journal of Radiation Oncology, Biology, Physics
1991 - Present	Editorial Board - Seminars in Radiation Oncology
1992 - 1998	Editorial Board - Radiation Oncology Investigations
1986, 1988	Program Committee - Radiation Research Society
1987	National Cancer Institute Equal Employment Opportunity Special Achievement Award
1987- 1990	Scientific Program Committee - American Society for Therapeutic Research and Oncology
1988 - 1992	NIH/NCI Radiation Study Section

HONORS AND OTHER SPECIAL SCIENTIFIC RECOGNITION, Continued:

March, 1989	Recipient of the 17th Radiation Research Award
1990 - 1993	Member, Inter Society Council for Radiation Oncology
1990 - 1995	Vice Chairman, Radiation Biology Committee, American Society for Therapeutic Radiology and Oncology
1990 - 1991	Councilor, Oxygen Club of Greater Washington, DC
1992 - 1993	President, Oxygen Club of Greater Washington, DC
1992 - 1998	Tumor Biology Committee, Radiation Therapy Oncology Group
1996-present	Associate Editor Cancer Research
1999-2000	Vice-President Elect Radiation Research Society
1997-2001	Member, DCS Promotion Tenure Review Panel National Cancer Institute
1998	National Cancer Institute Quality Work Life Award
1999	Program Committee - Radiation Research Society
1999-2001	Chair, DCS Promotion Tenure Review Panel National Cancer Institute
April, 2000	Academic Hall of Fame Honor Society of Phi Kappa Phi Austin Peay State University

HONORS AND OTHER SPECIAL SCIENTIFIC RECOGNITION, Continued:

May, 2000	Co-Editor of Book Lung Cancer: Principles and Practice, First & Second Edition
-----------	---

2000-2001	President-Elect Radiation Research Society
2001-2002	President Radiation Research Society
2002-2003	Past-President Radiation Research Society
February, 2001	Director's Award for Service Division of Clinical Science National Cancer Institute
June, 2001	John Yuhas Award for Outstanding Research in Radiation Biology Department of Radiation Oncology University of Pennsylvania
June, 2001 – Present	Editorial Academy International Journal of Oncology
September, 2001	Merit Award for Leadership National Cancer Institute
October, 2002 & 2004	Technology Transfer Award Center for Cancer Research, NCI
February 2005-Present	Member, NCI Animal Care and Use Committee
March 2005- Present	Member, Clinical Executive Committee, CCR, NCI
September, 2005	Federal Technology Transfer Award
October, 2005	NIH Merit Award for Outstanding Achievement in Radiation Research National Cancer Institute

PRESENT ADDRESS:

10516 Sweepstakes Rd.
Damascus, MD 20872
(301) 253-5999

RESEARCH INTERESTS:

Effects of Fractionation and Continuous Low Dose-Rate to Mammalian Cells

Modulation of Cellular Redox Potential--Oxidative Stress

Radiation Sensitizers/Protectors

Electron Paramagnetic Resonance--Imaging Free Radicals

ADMINISTRATIVE DUTIES:

Coordinate radiation biology seminar program of visiting scientists.

Teach the ROB radiotherapy residents a full course in radiation biology.

Administrative duties of Branch Chief, Radiation Biology Branch, NCI.

Administrative duties of Acting Branch Chief, Radiation Oncology Branch, NCI.

BIBLIOGRAPHY

1. Bender MA, Bedford JS, Mitchell JB. Mechanisms of chromosomal aberration production. II. Aberrations induced by 5-bromodeoxyuridine and visible light. Mutat Res 20:403-416, 1973.
2. Bedford JS, Mitchell JB. Dose-rate effects in synchronous mammalian cells in culture. Radiat Res 54:316-327, 1973.
3. Bedford JS, Mitchell JB. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Brit J Radiol 47:687-696, 1974.
4. Bedford JS, Mitchell JB, Griggs HG, Bender MA. Cell killing by gamma rays and beta particles from tritiated water and incorporated tritiated thymidine. Radiat Res 63:531-543, 1975.
5. Bedford JS, Mitchell JB. Mitotic accumulation of HeLa cells during continuous irradiation: Observations using time-lapse cinemicrography. Radiat Res 70:173-186, 1977.
6. Mitchell JB, Bedford JS. Dose-rate effects in synchronous mammalian cells in culture. II. A comparison of the life cycle of HeLa cells during continuous irradiation or multiple dose fractionation. Radiat Res 71:547-560, 1977.
7. Bedford JS, Mitchell JB, Griggs HG, Bender MA. Radiation-induced cellular reproductive death and chromosome aberrations. Radiat Res 76:573-586, 1978.
8. Mitchell JB, Bedford JS. Chromosome condensation and radiation-induced G2 arrest studied by the induction of premature chromosome condensation following cell fusion. Int J Radiat Biol 34:349-358, 1978.
9. Brown DB, Stack SM, Mitchell JB, Bedford JS. Visualization of the interphase chromosomes of *ornithogalum virens* and *muntiacus muntjak*. Cytobiologie 18: 398-412, 1979.
10. Raaphorst GP, Ramano SL, Mitchell JB, Bedford JS, Dewey WC. An examination of the intrinsic differences in heat and/or X-ray sensitivity of seven mammalian cell lines cultured and treated under identical conditions. Cancer Res 39:396-401, 1979.
11. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects on the life cycle and survival of S3 HeLa and V79 cells. Radiat Res 79:520-536, 1979.
12. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects on mammalian cells in culture. III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiat Res 79:537-551, 1979.

13. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects in plateau phase cultures of S3 HeLa and V79 cells. Radiat Res 79:552-567, 1979.
14. Mitchell JB, Bedford JS, Bailey SM. Observations of the first post-irradiation division of HeLa cells following continuous or fractionated exposure to gamma rays. Radiat Res 80:186-197, 1979.
15. Bedford JS, Mitchell JB, and Fox MH. Variations in response of several mammalian cell lines to low dose-rate irradiation. In: Meyn RE, and Withers HR, eds. Radiation Biology in Cancer Research. New York: Raven, 251-262, 1980.
16. Bromer RH, Mitchell JB, Soares N. Response of human hematopoietic precursor cells (CFUc) to hyperthermia and radiation. Cancer Res. 42:1261-1265, 1982.
17. Anderson LK, Stack SM, Mitchell JB. An investigation of the basis of a current hypothesis for the lack of G-banding in plant chromosomes. Experimental Cell Research 138:433-436, 1982.
18. Kinsella TJ, Mitchell JB, McPherson S, Russo A, Tietze F. *In vitro* X-ray sensitivity in ataxia telangiectasia homozygote and heterozygote skin fibroblasts under oxic and hypoxic conditions. Cancer Res 42:950-956, 1982.
19. Mitchell JB, Russo A, Kinsella TJ, Glatstein E. Glutathione elevation during thermotolerance induction and thermosensitization by glutathione depletion. Cancer Res. 43:987-991, 1983.
20. Mitchell JB, Kinsella TJ, Russo A, McPherson S, Rowland J, Smith BH, Kornblith PL, Glatstein E. Radiosensitization hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR). Int J Radiat Oncol Biol Phys 9:457-463, 1983.
21. Carney DN, Mitchell JB, Kinsella TJ. *In vitro* radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43:2806-2811, 1983.
22. Biaglow JE, Varnes ME, Astor M, Mitchell JB, Russo A. Intracellular thiols: involvement in drug metabolism and radiation response. In: Nygaard OF, Simic MG, eds. Radioprotectors and Anticarcinogens. New York: Academic Press, 203-236, 1983.
23. Mitchell JB, Russo A. Thiols, thiol depletion, and thermosensitivity. Radiat Res 95:471-485, 1983.
24. Mitchell JB, Russo A, Biaglow JE, McPherson S. Cellular glutathione depletion by diethyl maleate or buthionine sulfoximine: No effect of glutathione depletion on the Oxygen Enhancement Ratio. Radiat Res 96:422-428, 1983.

25. Morstyn G, Hsu SM, Kinsella TJ, Gratzner H, Russo A, Mitchell JB. Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody. J Clin Invest 72:844-1850, 1983.
26. Biaglow JE, Clark EP, Epp ER, Morse-Guadio M, Varnes ME, Mitchell JB. Non-protein thiols and the radiation response of A549 human lung carcinoma cells. Int J Radiat Biol 44:89-495, 1983.
27. Morstyn G, Fargion S, Moody T, Mitchell JB, Carney DN. Homogeneity and heterogeneity among small cell lung cancer cell lines (SCLC) from different metastatic sites in the same patient. In: Spitzky KH, Karrer K, eds. Proceedings 13th International Congress of Chemotherapy Vienna: Egermann, 281/37-281/41, 1983.
28. Carney DN, Mitchell JB, Kinsella TJ. Endocrine properties of lung cancer and their response to chemotherapy and radiation therapy *in vivo* and *in vitro*. In: Becker KL, Gazdar AF eds. The Endocrine Lung in Health and Disease W.B. Saunders Publishing Company, 603-611, 1984.
29. Russo A, Gianni L, Kinsella TJ, Klecker RW, Jenkins J, Rowland J, Glatstein E, Mitchell JB, Collins J, Myers CE. Pharmacologic evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Res 44:1702-1705, 1984.
30. Russo A, Mitchell JB, McPherson SJ. The effects of glutathione depletion on thermotolerance and heat stress protein synthesis. Brit J Cancer 49:753-758, 1984.
31. Kinsella TJ, Russo A, Mitchell JB, Rowland J, Jenkins J, Schwade JG, Myers CE, Collins JM, Speyer J, Kornblith P, Smith B, Kufta C, Glatstein E. A phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys 10:69-76, 1984.
32. Kinsella TJ, Mitchell JB, McPherson SJ, Miser J, Triche T, Glatstein E. *In vitro* radiation studies on Ewing's sarcoma cell lines and human bone marrow: Application to the clinical use of total body irradiation. Int J Radiat Oncol Biol Phys 10:1005-1011, 1984.
33. Morstyn G, Russo A, Carney DN, Karawya E, Wilson SH, Mitchell JB. Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J Natl Cancer Inst 73:801-807, 1984.
34. Mitchell JB, Morstyn G, Russo A, Kinsella TJ, Fornace A, McPherson SJ, Glatstein E. Differing sensitivity to fluorescent light in Chinese hamster cells containing equally incorporated quantities of BUdR versus IUdR. Int J Radiat Oncol Biol Phys 10:1447-1451, 1984.
35. Russo A, Mitchell JB, McPherson SJ, Friedman N. Alteration of bleomycin cytotoxicity by glutathione depletion or elevation. Int J Radiat Oncol Biol Phys 10:1675-1678, 1984.
36. Russo A, Mitchell JB. Radiation response of Chinese hamster cells after elevation of intracellular glutathione levels. Int J Radiat Oncol Biol Phys 10:1243-1247, 1984.

37. Morstyn G, Miller R, Russo A, Mitchell JB. 131 I-iodine conjugated antibody cell kill enhanced by bromodeoxyuridine. Int J Radiat Oncol Biol Phys 10:1437-1440, 1984.
38. Morstyn G, Kinsella TJ, Hsu S-M, Russo A, Gratzner H, and Mitchell JB. Identification of bromodeoxyuridine in normal cells following therapy: Relationship to complications. Int J Radiat Oncol Biol Phys 10:1441-1445, 1984.
39. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: Rationale, current status, and future prospects: Non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 10:1399-1406, 1984.
40. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Hsu S-M, Rowland J, and Glatstein E. Continuous intravenous infusions of bromodeoxyuridine (BUdR) as a clinical radiosensitizer. J Clin Oncol 2:1144-1150, 1984.
41. Knop RH, Chen C, Mitchell JB, Russo A, McPherson S, Cohen JS. Metabolic studies of mammalian cells by ^{31}P NMR using a continuous perfusion technique. Biochimica Biophysica Acta 804:275-284, 1984.
42. Biaglow JE, Issels RW, Gerweck LE, Varnes ME, Jacobson B, Mitchell JB, Russo A. Factors influencing the oxidation of cysteamine and other thiols: implications for hyperthermic sensitization and radiation protection. Radiat Res 100:298-312, 1984.
43. Foxall DL, Cohen JS, Mitchell JB. Continuous perfusion of mammalian cells embedded in agarose gel threads. Experimental Cell Res 154:521-529, 1984.
44. Morstyn G, Mitchell JB, Kinsella TJ. *In vivo* incorporation of bromodeoxyuridine into proliferating cells in the marrow and its effects on granulocyte-macrophage progenitor cells. Exp Hematol 13:289-294, 1985.
45. Knop RH, Chen CW, Mitchell JB, Russo A, McPherson S, Cohen JS. Adaptive cellular response to hyperthermia: ^{31}P NMR studies. Biochimica Biophysica Acta 845:171-177, 1985.
46. Mitchell JB, McPherson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells. Cancer Res 45:2008-2011, 1985.
47. DeGraff W, Russo A, Mitchell JB. Glutathione depletion greatly reduces neocarzinostatin cytotoxicity in Chinese hamster V79 cells. J Biol Chem 260:8312-8315, 1985.
48. Tochner Z, Mitchell JB, Harrington FS, Smith P, Russo DT, Russo A. Treatment of murine intraperitoneal ovarian ascitic tumor with hematoporphyrin derivative and laser light. Cancer Res 45:2983-2987, 1985.

49. Ling CC, Spiro IJ, Mitchell JB, Stickler R. The variation of OER with dose rate. Int J Radiat Oncol Biol Phys 11(7):1367-1373, 1985.
50. Russo A, Mitchell JB, DeGraff W, Spiro I, Gamson J. The effects of cellular glutathione elevation on the oxygen enhancement ratio. Radiat Res 103:232-239, 1985.
51. Russo A, Mitchell JB, DeGraff W, Friedman N, Gamson J. Depletion of cellular glutathione by exogenous spermine in V79 cells: Implications for spermine-induced hyperthermic sensitization. Cancer Res 45:4910-4914, 1985.
52. Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA. Specific killing of human melanoma cells by ¹²⁵I-labelled 9.2.27 monoclonal antibody. Cancer Res 45:5080-5087, 1985.
53. DeGraff WG, Mitchell JB. Glutathione dependence of neocarzinostatin cytotoxicity and mutagenicity in Chinese hamster V-79 cells. Cancer Res 45:4760-4762, 1985.
54. Mitchell JB, Morstyn G, Russo A, Carney DN. *In vitro* radiobiology of human lung cancer. Cancer Treatment Symposium 2:3-10, 1985.
55. Russo A, Mitchell JB. Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treatment Reports 69:1293-1296, 1985.
56. Russo A, Mitchell JB, Kinsella TJ, Morstyn G, Glatstein E. Determinants of radiosensitivity. Seminars in Oncology 12:332-349, 1985.
57. Mitchell JB, Karawya E, Kinsella TJ, Wilson SH. Measurement of DNA polymerase β in skin fibroblast cell lines from patients with ataxia telangiectasia. DNA Repair Reports 146:295-300, 1985.
58. Kinsella TJ, Russo A, Mitchell JB, Collins JM, Rowland J, Wright D, Glatstein E. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 11:1941-1946, 1985.
59. Samuni A, Bump EA, Mitchell JB, Brown JM. Enhancement of misonidazole cytotoxicity by iron. Int J Radiat Biol 49:77-83, 1986.
60. Fornace AJ, Kinsella TJ, Dobson PA, Mitchell JB. Repair of ionizing radiation DNA base damage in ataxia telangiectasia cells. Cancer Res 46:1703-1706, 1986.
61. Boven E, Lindmo T, Mitchell JB, Bunn PA, Jr. Selective cytotoxicity of ¹²⁵I-labeled monoclonal antibody T101 in human malignant T cell lines. Blood 67:2: 429-435, 1986.
62. Russo A, DeGraff W, Friedman N, Mitchell JB. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46:2845-2848, 1986.

63. Ashwell JD, Schwartz RH, Mitchell JB, Russo A. Effect of gamma radiation on resting B. lymphocytes. I. Oxygen-dependent damage to the plasma membrane results in increased permeability and cell enlargement. J Immunol 136:3649-3656, 1986.
64. Tochner Z, Mitchell JB, Smith P, Harrington F, Glatstein E, Russo D, Russo A. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer 53:733-736, 1986.
65. Kinsella TJ, Dobson PP, Russo A, Mitchell JB, Fornace AJ. Modulation of X ray DNA damage by SR-2508 + buthionine sulfoximine. Int J Radiat Oncol Biol Phys 12:1127-1130, 1986.
66. Mitchell JB, Phillips TL, DeGraff W, Carmichael J, Rajpal RK, Russo A. The relationship of SR-2508 sensitizer enhancement ratio to cellular glutathione levels in human tumor cell lines. Int J Radiat Oncol Biol Phys 12:1143-1146, 1986.
67. Russo A, Tochner Z, Phillips T, Carmichael J, DeGraff W, Friedman N, Fisher J, Mitchell JB. *In vivo* modulation of glutathione by buthionine sulfoximine effect on marrow response to melphalan. Int J Radiat Oncol Biol Phys 12:1187-1189, 1986.
68. Carmichael J, Friedman N, Tochner Z, Adams D, Wolf CR, Ihde DC, Mitchell, JB, Russo, A. Inhibition of the protective effect of cyclophosphamide by pre-treatment with buthionine sulfoximine. Int J Radiat Oncol Biol Phys 12:1191-1193, 1986.
69. Samuni A, Carmichael AJ, Russo A, Mitchell JB, Riesz P. The distinction between exo- and endocellular spin trapping of oxygen radicals. Superoxide and Dismutase in Chemistry, Biology and Medicine, 119-121, 1986.
70. Fornace AJ, Mitchell JB. Induction of B2 RNA polymerase III transcription by heat shock: Enrichment for heat shock induced sequences in rodent cells by hybridization subtraction. Nucleic Acids Research. 14:5793-5811, 1986.
71. Russo A, Carmichael J, Friedman N, DeGraff W, Tochner Z, Glatstein E, Mitchell JB. The roles of intracellular glutathione in antineoplastic chemotherapy. Int J Radiat Oncol Biol Phys 12:1347-1354, 1986.
72. Mitchell JB, Russo A, Kinsella TJ, Glatstein E. The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy. Int J Radiat Oncol Biol Phys 12: 1513-1518, 1986.
73. Russo A, DeGraff W, Kinsella T, Gamson J, Glatstein E, Mitchell JB. Potentiation of chemotherapy cytotoxicity following iododeoxyuridine incorporation in Chinese hamster cells. Int J Radiat Oncol Biol Phys 12:1371-1374, 1986.
74. Samuni A, Carmichael AJ, Russo A, Mitchell JB, Riesz P. On the spin trapping and ESR detection of oxygen-derived radicals generated inside cells. Proc Natl Acad Sci 83:7593-7597, 1986.

75. Phillips TL, Mitchell JB, DeGraff W, Russo A, Glatstein E. Variation in sensitizing efficiency for SR-2508 in human cells dependent on glutathione content. Int J Radiat Oncol Biol Phys 12:1627-1635, 1986.
76. Kinsella TJ, Dobson PP, Mitchell JB. Interaction of iododeoxyuridine and its primary metabolite, iodouracil on radiation response. Int J Radiat Oncol Biol Phys 12:1519-1522, 1986.
77. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium based semi-automated colorimetric assay: I Assessment of chemosensitivity testing. Cancer Res 47:936-942, 1987.
78. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium based semi-automated colorimetric assay: II Assessment of radiosensitivity. Cancer Res 47:943-946, 1987.
79. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ, Jr. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13:733-739, 1987.
80. Miller RW, DeGraff W, Kinsella TJ, Mitchell JB. Evaluation of incorporated iododeoxyuridine cellular radio sensitization by photon activation therapy. Int J Radiat Oncol Biol Phys 13:1193-1197, 1987.
81. Mitchell JB, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Brit J Cancer 55:96-104, 1987.
82. Mitchell JB, Cook JA Russo A. The influence of thiol modulation of the chemotherapy and radiation response. In: Fielden EM, Fowler JF, Hendry JH, Scott D. eds. Eight International Congress of Radiation Research; Taylor & Francis Ltd., 768-773, 1987.
83. Mitchell JB, Gamson J, Russo A, Friedman N, DeGraff W, Carmichael J, Glatstein E. Chinese hamster pleiotropic multidrug-resistant cells are not radioresistant. NCI Monographs 6:187-191, 1988.
84. Kurtzman S, Russo A, Mitchell JB, DeGraff W, Sindelar WF, Brechbiel MW, Gansow OA, Friedman AM, Hines JJ, Atcher RW. ²¹²Bismuth linked to an anti-pancreatic carcinoma antibody: A model for alpha particle emitting radioimmunotherapy. J Natl Cancer Inst 80:449-452, 1988.
85. Mitchell JB. Potential applicability of non-clonogenic measurements to clinical oncology. Radiation Res 114:401-414, 1988.
86. Mitchell JB. Glutathione modulation and cancer treatment. ISI Atlas Sci-Pharmacol 2:155-169, 1988.

87. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57:540-547, 1988.
88. Brown JM, Hall EJ, Hirst DG, Kinsella TJ, Kligerman MM, Mitchell JB, Travis EJ, Valeriote F. Chemical modification of radiation and chemotherapy. Am J Clin Oncol 11:288-303, 1988.
89. Hall EJ, Astor M, Bedford J, Borek C, Curtis SB, Fry M, Geard C, Hei T, Mitchell JB, Oleinick N, Rubin J, Tu A, Ullrich R, Waldren C, Ward J. Basic Radiobiology. Am J Clin Oncol 11:220-252, 1988.
90. Carmichael J, Park JG, DeGraff WG, Gamson J, Gazdar AF, Mitchell JB. Radiation sensitivity and study of glutathione and related enzymes in human colorectal cancer cell lines. Eur J Cancer Clin Oncol 24:1219-1224, 1988.
91. Mitchell JB, Biaglow JE, Russo A. Role of glutathione and other endogenous thiols in radiation protection. Pharmac Ther 39:269-274, 1988.
92. Kondo T, Gamson J, Mitchell JB, Riesz P. Free radical formation and cell lysis induced by ultrasound in the presence of different rare gases. Int J Radiat Biol 54: 955-962, 1988.
93. Carmichael J, Mitchell JB, Friedman N, Gazdar AF, Russo A. Glutathione and related enzyme activity in human lung cancer cell lines. Br J Cancer 58:437-440, 1988.
94. Mitchell JB, Russo A, Carmichael J, Glatstein E. Glutathione as a predictor of tumor response. In: Chapman JD, Peters LJ, Withers HR eds. Prediction of Tumor Treatment Response; New York: Pergamon Press, Inc., 157-174, 1989.
95. Gazdar AF, Chung-Ming T, Park J-G, Ihde D, Mulshine J, Carmichael J, Mitchell JB, Minna JD. *In vitro* assays for predicting clinical response in human lung cancer. In: Chapman JD, Peters LJ, Withers HR eds. Prediction of Tumor Treatment Response; New York: Pergamon Press, Inc., 175-186, 1989.
96. Atcher RW, DeGraff WG, Moore M, Grdina DJ, Mitchell JB. Halogenated pyrimidines as radiosensitizers for high LET radiation. Radiation Res 117:351-355, 1989.
97. Matthews W, Cook J, Mitchell JB, Perry RR, Evans S, Pass HI. *In vitro* photodynamic therapy of human lung cancer: Investigation of dose-rate effects. Cancer Res 49:1718-1721, 1989.
98. Mitchell JB, Cook JA, DeGraff WG, Glatstein E, Russo A. Glutathione modulation in cancer treatment: Will it work? Int J Radiat Oncol Biol Phys 16:1289-1295, 1989.
99. Cook JA, Russo A, Pass HI, Iype S, Mitchell JB. Use of Monochlorobimane for glutathione measurements in hamster and human tumor cell lines. Int J Radiat Oncol Biol Phys 16:1321-1324, 1989.

100. Phillips TL, Mitchell JB, DeGraff WG, Russo A, Albright N, Rajpal R. Modification of SR 2508 sensitization in hypoxic V79 cells by manipulation of glutathione levels. Int J Radiat Oncol Biol Phys 16:1335-1339, 1989.
101. Phillips TL, Bodell WJ, Uhl V, Ross GY, Rasmussen J, Mitchell JB. Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys 16:1251-1255, 1989.
102. DeGraff WG, Russo A, Gamson J, Mitchell JB. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione. Int J Radiat Oncol Biol Phys 16:1021-4, 1989.
103. Carmichael J, DeGraff W, Gamson J, Gazdar AF, Mitchell JB. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25:527-534, 1989.
104. Russo A, Mitchell JB, Pass HI, Glatstein E. Photodynamic Therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practices of Oncology; Philadelphia: Lippincott, 2449-2461, 1989.
105. Cook JA, Mitchell JB. Viability measurements in mammalian cell systems. Analytical Biochemistry 179:1-7, 1989.
106. Mitchell JB, Russo A, Cook JA, Glatstein E. Tumor cell drug and radiation resistance: does an interrelationship exist? In: Ozols RF, eds. Drug Resistance; Kluwer Academic Publishers, 189-203, 1989.
107. Matthews W, Rizzoni W, Mitchell JB, Russo A, Pass H. *In vitro* Photodynamic therapy of human lung cancer. J Surg Res 47:276-281, 1989.
108. Alegria AE, Samuni A, Mitchell JB, Riesz P, Russo A. Free radicals induced by adriamycin-sensitive and resistant cells: A spin-trapping study. Biochemistry 28:8653-8658, 1989.
109. Mitchell JB, Russo A, Cook JA, Straus KL, Glatstein E. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. Int J Radiat Biol 56:827-836, 1989.
110. Mitchell JB, Samuni A, Krishna CM, DeGraff WG, Ahn MS, Russo A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry 29:2802-2807, 1990.
111. Perry RR, Matthews W, Mitchell JB, Russo A, Evans S, Pass HI. Sensitivity of different human lung cancer histologies to photodynamic therapy. Cancer Res 50:4272-4276, 1990.
112. DeGraff WG, Russo A, Friedman N, Mitchell JB. Misonidazole hypoxic cytotoxicity and chemosensitization in two cell lines with different intracellular glutathione levels. Eur J Cancer 26:17-20, 1990.

113. Samuni A, Krishna CM, Mitchell JB, Collins CR, Russo A. Superoxide reaction with nitroxides. Free Radical Res Commun 9:241-249, 1990.
114. Mitchell JB, Cook JA, Russo, A. Biological basis for phototherapy. In: Morstyn G, Kaye AH, eds. Phototherapy of Cancer: Harwood Academic Publishers, 1-22, 1990.
115. Russo A, Mitchell JB. Future directions for photodynamic therapy. In: Morstyn G, Kaye AH, eds. Phototherapy of Cancer: Harwood Academic Publishers, 215-222, 1990.
116. Bernstein EF, Thomas GF, Smith PD, Mitchell JB, Glatstein E, Kantor GR, Spielvogel RL, Maiese SC, Russo A. Response of black and white guinea pig skin to photodynamic treatment using 514-Nm light and dihematoporphyrin ether. Arch Dermatol 126:1303-1307, 1990.
117. Tochner Z, Barnes M, Mitchell JB, Orr K, Glatstein E, Russo A. Protection by indomethacin against acute radiation esophagitis. Digestion 47:81-87, 1990.
118. Goffman TE, Raubitschek A, Mitchell JB, Glatstein E. The emerging biology of modern radiation oncology. Cancer Res 50:7735-7744, 1990.
119. Samuni A, Ahn M, Krishna CM, Mitchell JB, Russo A. SOD-like activity of 5-membered nitroxide spin labels. In: Emerit I, Packer L, Auclair C, eds. Antioxidants in Therapy and Preventive Medicine: Plenum Press, 85-92, 1990.
120. Samuni A, Godinger D, Aronovitch J, Russo A, Mitchell JB. Nitroxides block DNA scission and protect cells from oxidative damage. Biochemistry 30:555-561, 1991.
121. Tochner Z, Mitchell J, Hoekstra H, Smith P, DeLuca A, Barnes M, Harrington F, Manyak M, Russo D, Russo A. Photodynamic therapy of the canine peritoneum: Normal tissue response to intraperitoneal and intravenous photofrin followed by 630 nm light. Lasers in Surgery and Medicine. 11:158-164, 1991.
122. Cook J, Iype S, Mitchell JB. Differential specificity of monochlorobimane for isozymes of human and rodent glutathione S-transferases. Cancer Res 51:1606-1612, 1991.
123. Pogrebniak H, Matthews BS, Mitchell JB, Russo A, Samuni A, Pass H. Spin trap protection from tumor necrosis factor cytotoxicity. J Surg Res 50:469-474, 1991.
124. Samuni A, Winkelsberg D, Pinson A, Hahn SM, Mitchell JB, Russo A. Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage. J Clin Invest 87:1526-1530, 1991.
125. Samuni A, Mitchell JB, DeGraff W, Krishna CM, Samuni U, Russo A. Nitroxide SOD-mimics: modes of action. Free Radic Biol Med 12-13:187-194, 1991.
126. Hahn SM, Krishna CM, Samuni A, Mitchell JB, Russo A. Mn(III)-desferrioxamine superoxide dismutase-mimic: alternative modes of action. Arch Biochem Biophys 288:1:215-219, 1991.

127. Bernstein EF, Glass JM, DeGraff WG, Schlegel R, Black C, Fisher JM, Cook SN, Glatstein E, Russo A, Mitchell JB. *In vitro* photodynamic treatment of normal and human papilloma virus-transfected keratinocytes with photofrin II and red light. Arch Dermatol 127:683-687, 1991.
128. Spiro IJ, McPherson S, Cook JA, Ling CC, DeGraff W, Mitchell JB. Enhanced radiosensitization at low dose rate using non-lethal hyperthermia. Radiat Res 127:111-114, 1991.
129. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, Hahn SM, Gamson J, Russo A. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic TEMPOL. Arch Biochem Biophys 289:62-70, 1991.
130. Mitchell JB, Glatstein E. Radiation Oncology. Past achievements and on-going controversies. Cancer Res 51:5065-5073, 1991.
131. Cook JA, Pass HI, Iype SN, Friedman N, DeGraff W, Russo A, Mitchell JB. Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res 51:4287-4294, 1991.
132. Bernstein EF, Harisiadis L, Salomon G, Norton J, Sollberg S, Uitto J, Glatstein E, Glass J, Talbot T, Russo A, Mitchell JB. Transforming growth factor- β improves healing of radiation-impaired wounds. J Invest Dermatol 97:430-434, 1991.
133. Delaney TF, Smith PD, Thomas GF, Tochner ZA, Sindelar WF, Pass HI, Harrington FS, Bonner RF, Mitchell JB. A light-diffusing device for intraoperative photodynamic therapy in the peritoneal or pleural cavity. J Clin Laser Med Surg Oct:361-366, 1991.
134. Krishna MC, DeGraff W, Tamura S, Gonzalez FJ, Samuni A, Russo A, Mitchell JB. Mechanisms of hypoxic and aerobic cytotoxicity of Mitomycin-C in Chinese hamster V79 cells. Cancer Res 51:6622-6628, 1991.
135. Kaufman D, Mitchell JB, Russo A. Glutathione, a determinant of response to cancer treatment. Medical Radiology Continuous Infusion Chemotherapy & Radiation 85-9, 1991.
136. Uckun FM, Mitchell JB, Obuz V, Park CH, Waddick K, Friedman N, Oubaha L, Min WS, Song CW. Radiation sensitivity of human B-lineage lymphoid precursor cells. Int J Radiat Oncol Biol Phys 21(6):1553-60, 1991.
137. DeGraff WG, Krishna MC, Russo A, Mitchell JB. Antimutagenicity of a low molecular weight superoxide dismutase mimic against oxidative mutagens. Environ Mol Mutagen 19:21-6, 1992.

138. Mitchell JB, Coleman CN. Keynote address: Biochemical modification of therapeutic response. Int J Radiat Oncol Biol Phys 22:483-4, 1992.
139. Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Steinberg SM, Cook J, Mitchell JB, Katz D, Smith R, Glatstein E. Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol 10(2):264-68, 1992.
140. Goffman TE, Cuscata D, Glass J, Hahn S, Krishna CM, Lupton G, Mitchell JB. Topical application of nitroxide protects radiation-induced alopecia in guinea pigs. Int J Radiat Oncol Biol Phys 22:803-6, 1992.
141. Mitchell JB, Cook JA, Krishna MC, Hahn S, Goffman T, Glatstein E. Prospect for modifying the radiosensitivity of oxic tumor cells. In: Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF, eds. Radiation Research: A Twentieth-Century Perspective; vol. 2. New York: Academic Press, 745-50, 1992.
142. Garg PK, Garg S, DeGraff WG, Zalutsky MR, Mitchell JB. 4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys 22(3):593-6, 1992.
143. Cook JA, Glass J, Lebovics R, Bobo H, Pass H, DeLaney TF, Oldfield EH, Mitchell JB, Glatstein E, Goffman TE. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res 52:719-25, 1992.
144. Krishna CM, Liebmann JE, Kaufman D, DeGraff W, Hahn SM, McMurphy T, Mitchell JB, Russo A. The catecholic metal sequestering agent 1,2-dihydroxybenzene-3,5-disulfonate confers protection against oxidative cell damage. Arch Biochem Biophys 294(1):98-106, 1992.
145. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, Samuni A, Sprague M, Venzon D, Glatstein E, Mitchell JB, Russo A. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 52:1750-3, 1992.
146. Biaglow JE, Mitchell JB, Held K. The importance of peroxide and superoxide in the x-ray response. Int J Radiat Oncol Biol Phys 22:665-9, 1992.
147. Krishna MC, Grahame DA, Samuni A, Mitchell JB, Russo A. Oxoammonium cation intermediate in the nitroxide-catalyzed dismutation of superoxide. PNAS 89:5537-41, 1992.
148. Pass HI, DeLaney T, Russo A, Mitchell J, Smith P, Friauf W, Thomas G. Feasibility of intrapleural photodynamic therapy: The first eight patients. SPIE 1645:1-9, 1992.
149. Pogrebniak HW, Merino MJ, Hahn SM, Mitchell JB, Pass HI. Spin trap salvage from endotoxemia: The role of cytokine down-regulation. Surgery 112(2):130-9, 1992.

150. DeGraff WG, Krishna MC, Kaufman D, Mitchell JB. Nitroxide-mediated protection against x-ray- and neocarzinostatin-induced DNA damage. Free Radic Biol Med 13:479-87, 1992.
151. Hahn SM, Wilson L, Krishna MC, Liebmann J, DeGraff WG, Gamson J, Samuni A, Venzon D, Mitchell JB. Identification of nitroxide radioprotectors. Radiat Res 132:87-93, 1992.
152. Leung SW, Mitchell JB, al-Nabulsi I, Friedman N, Newsome J, Belldegrin A, Kasid U. Effect of L-buthionine sulfoximine on the radiation response of human renal carcinoma cell lines. Cancer 71(7):2276-85, 1993.
153. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53:2066-70, 1993.
154. Pogrebniak HW, Matthews W, Black C, Russo A, Mitchell JB, Smith P, Roth JA, Pass HI. Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg Oncol 2:31-42, 1993.
155. Cook JA, Mitchell JB. Radiation and chemotherapy toxicity: mechanisms of resistance. In: John MJ, Flam MS, Legha SS, Phillips TL, eds. Chemoradiation: an integrated approach to cancer treatment. Lea and Febiger: 159-78, 1993.
156. Bernstein EF, Sullivan FJ, Mitchell JB, Salomon GD, Glatstein E. Biology of chronic radiation effect on tissues and wound healing. Clinics in Plastic Surgery 20:435-53, 1993.
157. Bourg J, Krishna MC, Mitchell JB, Tschudin RG, Pohida TJ, Friauf WS, Smith PD, Metcalfe J, Harrington F, Subramanian S. Radiofrequency FT EPR spectroscopy and imaging. J Mag Reson 102(B):112-5, 1993.
158. Wink D, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci 90:9813-7, 1993.
159. Mitchell JB, Wink D, DeGraff WG, Gamson J, Keefer L, Krishna MC. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53:5845-8, 1993.
160. Hahn SM, Liebmann JE, Cook JA, Teague D, Fisher J, Goldspiel B, Venzon D, Mitchell JB, Kaufman D. Taxol in combination with Doxorubicin or etoposide: possible antagonism *in vitro*. Cancer 72:2705-11, 1993.
161. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel (Taxol ®) in human tumour cell lines. Br J Cancer 68:1104-9, 1993.
162. Liebmann JE, Cook JA, Mitchell JB. Cremophor EL solvent for paclitaxel and toxicity [letter]. Lancet 342:1428, 1993.

163. Pass HI, DeLaney TF, Tochner Z, Smith PE, Temeck BK, Pogrebniak HW, Kranda KC, Russo A, Friauf WS, Cole JW, Mitchell JB, Thomas G. Intraleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1:28-37, 1994.
164. Tokarek R, Bernstein EF, Sullivan F, Uitto J, Mitchell JB. Effect of therapeutic radiation on wound healing. Clin Dermatol 12:57-70, 1994.
165. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. The influence of Cremophor EL on the cycle effects of paclitaxel (Taxol ®) in human tumor cell lines. Cancer Chemother Pharmacol 33:331-9, 1994.
166. Liebmann JE, Cook JA, Fisher J, Teague D, Mitchell JB. *In vitro* studies of paclitaxel (Taxol®) as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-6, 1994.
167. Hahn SM, Krishna MC, Samuni A, DeGraff W, Cusccla DO, Johnstone P, Mitchell JB. Potential use of nitroxides in radiation oncology. Cancer Res 54:2006-10, 1994.
168. Liebmann JE, DeLuca AM, Epstein A, Steinberg SM, Morstyn G, Mitchell JB. Protection from lethal irradiation by the combination of stem cell factor and Tempol. Radiat Res 137:400-4, 1994.
169. Liebmann JE, Cook JA, Fisher J, Teague D, Mitchell JB. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol ®). Int J Radiat Oncol Biol Phys 29:559-64, 1994.
170. Krishna MC, Dewhirst MW, Friedman HS, Cook JA, DeGraff W, Samuni A, Russo A, Mitchell JB. Hyperthermic sensitization by the radical initiator 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH). I. *In vitro* studies. Int J Hyperthermia 10:271-281, 1994.
171. Liebmann JE, Cook JA, Teague D, Fisher J, Mitchell JB. Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol®). Anti-Cancer Drugs 5:287-92, 1994.
172. Liebmann J, Bourg J, Krishna CM, Glass J, Cook JA, Mitchell JB. Pharmacokinetic properties of nitroxide-labeled albumin in mice. Life Sci 54:503-9, 1994.
173. Tuttle SW, Hazard L, Koch CJ, Mitchell JB, Coleman CN, Biaglow JE. Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air. Int J Radiat Oncol Biol Phys 29:357-62, 1994.
174. Liebmann J, DeLuca AM, Coffin D, Keefer LK, Venzon D, Wink DA, Mitchell JB. *In vivo* radiation protection by nitric oxide modulation. Cancer Res 54:3365-8, 1994.
175. Peden DB, Dailey L, DeGraff W, Mitchell JB, Lee JG, Kaliner MA, Hohman RJ. Hydrogen peroxide effects on rat mast cell function. Am J Physiol 267: L85-93, 1994.

176. DeGraff W, Hahn SM, Mitchell JB, Krishna MC. Free radical modes of cytotoxicity of adriamycin and streptonigrin. Biochem Pharmacol 48:1427-35, 1994.
177. Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval F, Laval J, Cook JA, Krishna MC, DeGraff WG, Mitchell JB. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O₂ reaction. Chem Res Toxicol July/Aug:519-25, 1994.
178. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glatstein E. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30:583-90, 1994.
179. Herscher LL, Krishna MC, Cook JA, Coleman CN, Biaglow JE, Tuttle SW, Gonzalez FJ, Mitchell JB. Protection against SR4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int J Radiat Oncol Biol Phys 30:879-85, 1994.
180. Bernstein EF, Harisiadis L, Salomon GD, Harrington F, Mitchell JB, Uitto J, Glatstein E, Russo A. Healing impairment of open wounds by skin irradiation. J Dermatol Surg Oncol 20:757-60, 1994.
181. Wink DA, Hanbauer I, Laval F, Cook JA, Krishna MC, Mitchell JB. Nitric oxide protects against the cytotoxic effects of reactive oxygen species. Ann NY Acad Sci 738:265-278, 1994.
182. Hahn SM, Krishna CM, Mitchell JB. New directions for free radical cancer research and medical applications. In: Armstrong D, ed. Free Radicals in Diagnostic Medicine, Plenum Press, New York: 241-51, 1994.
183. Johnstone PAS, DeGraff WG, Mitchell JB. Protection from radiation-induced chromosomal aberrations by the nitroxide tempol. Cancer 75:2323-2327, 1995.
184. Bernstein EF, Smith PD, Thomas GF, Xie H, Mitchell JB, Glatstein E, Russo A. A diffusing sphere which delivers homogeneous laser light for use in photodynamic therapy. J Dermatol Sci 9:195-202, 1995.
185. Wink DA, Cook JA, Krishna MC, Hanbauer I, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against alkyl peroxide mediated cytotoxicity. Further Insights into the role nitric oxide plays in oxidative stress. Arch Biochem Biophys 319:402-407, 1995.
186. Liebmann J, DeLuca AM, Coffin D, Venzon DJ, Wink DA, Mitchell JB. Nitric oxide modulation enhances the *in vivo* protection from lethal irradiation by stem cell factor. Radiat Oncol Invest 2:264-268, 1995.
187. Hahn SM, Lepinski DL, DeLuca AM, Mitchell JB, Pellmar TC. Neurophysiological consequences of nitroxide anti-oxidants. Can J Physiol Pharmacol 73:399-403, 1995.

188. Cook JA, Mitchell JB. Measurements of thiols in cell populations from tumor and normal tissue. Methods in Enzymol 251:203-212, 1995.
189. Pacelli R, Wink DA, Cook JA, Krishna MC, DeGraff W, Friedman N, Tsokos M, Samuni A, Mitchell JB. Nitric oxide potentiates hydrogen peroxide-induced killing of *Escherichia coli*. J Exp Med 182:1469-1479, 1995.
190. Wink DA, Cook JA, Pacelli R, Liebmann J, Krishna MC, Mitchell JB. Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Toxicol Lett 82-83:221-226, 1995.
191. Sullivan FJ, Krishna MC, Mitchell JB. Radiation biology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Lippincott-Raven, 219-249, 1996.
192. Wink DA, Hanbauer I, Grisham MB, Laval F, Nims RW, Laval J, Cook J, Pacelli R, Liebmann J, Krishna M, Ford PC, Mitchell JB. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Curr Top Cell Regul 34:159-87, 1996.
193. Sullivan FJ, Carmichael J, Glatstein E, Mitchell JB. Radiation biology of lung cancer. J Cell Biochem suppl 24:152-159, 1996.
194. Cook JA, Kim SY, Teague D, Krishna MC, Pacelli R, Mitchell JB, Vodovotz Y, Nims RW, Christodoulou D, Miles AM, Grisham MB, Wink DA. Convenient colorimetric and fluorometric assays for s-nitrosothiols. Anal Biochem 238:150-158, 1996.
195. Kuppusamy P, Wang P, Zweir J, Krishna MC, Mitchell JB, Ma L, Trimble CE, Hsia CJ. Electron paramagnetic resonance imaging of rat heart with nitroxide and polynitroxyl-albumin. Biochem 35:7051-7057, 1996.
196. Wink DA, Cook JA, Pacelli R, DeGraff W, Gamson J, Liebmann JE, Krishna MC, Mitchell JB. The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity. A direct correlation between nitric oxide formation and protection. Arch Biochem Biophys 331:241-248, 1996.
197. Mitchell JB, Cook JA, Krishna MC, DeGraff W, Gamson J, Fisher J, Christodoulou D, Wink DA. Radiosensitization by nitric oxide releasing agents. Br J Cancer 74:S181-S184, 1996.
198. Wink DA, Leibmann J, Pacelli R, Cook JC, DeLuca AM, Coffin D, DeGraff W, Gamson J, Krishna MC, Mitchell JB. Possible Roles for NO donors in Cancer Treatment. In: Stamler J, Gross S, Moncada S and Higgs A, Eds. The Biology of Nitric Oxide. Vol. 5. London:Portland Press 39-40, 1996.
199. Wink DA, Grisham M, Mitchell JB, Ford PC. Direct and Indirect Effects of Nitric Oxide. Biologically Relevant Chemical Reactions in Biology of NO. Methods in Enzymol 268:12-31, 1996.

200. Krishna MC, Samuni A, Taira J, Goldstein S, Mitchell JB, Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins: Kinetics and mechanisms. J Biol Chem 271 :26018-26025, 1996.
201. Krishna MC, Russo A, Mitchell JB, Goldstein S, Dafni H, Samuni A. Do nitroxide antioxidants act as scavengers of O₂- or as SOD-mimics? J Biol Chem 271:26026-26031, 1996.
202. Cuscela D, Coffin D, Lupton GP, Cook JA, Krishna MC, Bonner RF, Mitchell JB. Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J Sci Am 2:273-278, 1996.
203. Hahn SM, Sullivan FJ, DeLuca AM, Sprague M, Hampshire VA, Krishna MC, Russo A, Mitchell JB. Protection of mitomycin C induced skin extravasation with the nitroxide, 3-carbamoyl-PROXYL (3-CP). Int J Oncol 10:119-123, 1997.
204. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, DeGraff W, Gamson J, Vodovotz Y, Russo A, Mitchell JB. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide: Biology and Chemistry 1:88-94, 1997.
205. Twomey P, Taira J, DeGraff WG, Mitchell JB, Russo A, Krishna MC, Hankovsky OH, Frank L, Hideg K. Direct evidence for *in vivo* nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy. Free Radic Biol Med 22:909-916, 1997.
206. Bourassa J, DeGraff W, Kudo S, Wink DA, Mitchell JB, Ford PC. Photochemistry of Roussin's red salt, Na₂[Fe₂S₂(NO)₄], and of Roussin's black salt, NH₄[Fe₄S₃(NO)₇]. *In situ* nitric oxide generation to sensitize γ -radiation induced cell death. J Am Chem Soc 119:2853-2860, 1997.
207. Hahn SM, Sullivan FJ, DeLuca AM, Krishna CM, Wersto N, Venzon D, Russo A, Mitchell JB. Evaluation of tempol radioprotection in a murine tumor model. Free Radic Biol Med 22:1211-1216, 1997.
208. Chen AY, Okunieff P, Pommier Y, Mitchell JB. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Research 57:1529-1536, 1997.
209. Wink DA, Cook JA, Kim SY, Vodovotz Y, Pacelli R, Krishna MC, Russo A, Mitchell JB, Jourdeuil D, Miles AM, Grisham MB. Superoxide modulates the oxidation and Nitrosation of thiols by NO-derived reactive intermediates. Chemical aspects involved in the balance between oxidative and nitrosative stress. J Biol Chem 272:11147-11151, 1997.

210. Cook JA, Krishna MC, Pacelli R, DeGraff W, Liebmann J, Mitchell JB, Russo A, Wink DA. Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 76:325-334, 1997.
211. Johnstone PAS, Rohde DC, Saunders EL, Mitchell JB. Combining intraoperative and conventional external radiotherapy doses: A biology-based approach. In: Vaeth JM, Ed. Intraoperative Radiation Therapy in the Treatment of Cancer. Front Radiat Therap Oncol, Basel, Karger, 31:18-21, 1997.
212. Vodovotz Y, Hsing A, Cook JA, Miller RW, Wink DA, Ritt DM, Mitchell JB, Danielpour D. Qualitative and quantitative analysis of DNA fragmentation using digital imaging. Anal Biochem 250: 147-152, 1997.
213. Murugesan R, Cook JA, Devasahayam N, Afeworki M, Subramanian S, Tschudin R, Larsen JA, Mitchell JB, Russo A, Krishna MC. *In vivo* imaging of a stable paramagnetic probe by pulsed-radiofrequency electron paramagnetic resonance spectroscopy. Magn Reson Med 38:409-414, 1997.
214. Hauck ML, Coffin DO, Dodge RK, Dewhirst MW, Mitchell JB, Zalutsky MR. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int J Hyperthermia 13: 307-316, 1997.
215. Hahn SM, Mitchell JB, Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med 23:879-884, 1997.
216. Hahn SM, Krishna CM, Mitchell JB. Stable free radicals as radiation protectors. In Bump EA, Malaker K, Eds. Radioprotectors: Chemical, Biological, and Clinical Perspectives. CRC, Boca Raton, 111-126, 1997.
217. Mitchell JB. A commentary on: Expression of p53, glutathione S-transferase-r, Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. Breast Diseases: A Year Book Quarterly 8:379-380, 1998.
218. Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, Liebmann J. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635-641, 1998.
219. Vodovotz Y, Kopp JB, Takeguchi H, Shrivastav S, Coffin D, Lucia MS, Mitchell JB, Webber R, Letterio J, Wink DA, Roberts AB. Increased mortality, blunted production of nitric oxide, and increased production of TNF- α in endotoxemic TGF- β 1 transgenic mice. J Leukoc Biol, 63:31-39, 1998.
220. Wink DA, Feelisch M, Fukuto J, Christodoulou D, Jourdain D, Grisham MB, Vodovotz Y, Cook JA, Krishna M, DeGraff WG, Kim S, Gamson J, Mitchell JB. The Cytotoxic Mechanism of Nitroxyl: Possible Implications for the Pathophysiological Role of NO. Arch Biochem Biophys 351:66-74, 1998.

221. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 12:825-832, 1998.
222. Kuppusamy P, Afeworki M, Shankar RA, Coffin D, Krishna MC, Hahn SM, Mitchell JB, Zweier JL. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res 58:1562-1568, 1998.
223. Murugesan R, Afeworki M, Cook JA, Devasahayam N, Tschudin R, Mitchell JB, Subramanian S, Krishna MC. A broadband pulsed radio frequency electron paramagnetic resonance spectrometer for biological applications. Rev Sci Instrum 69:1869-1876, 1998.
224. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19:711-721, 1998.
225. Robinson KA, Cook JA, Mitchell JB, Murugesan R, Krishna MC, Subramanian S. FT-EPR with a nonresonant probe: Use of a truncated coaxial line. J Magn Reson 132:255-259, 1998.
226. Afeworki M, Miller NR, Devasahayam N, Cook JA, Mitchell JB, Subramanian S, Krishna MC. Preparation and EPR studies of lithium phthalocyanine radical as an oxymetric probe. Free Radic Biol Med 25:72-78, 1998.
227. Wink DW, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25:434-456, 1998.
228. Krishna MC, DeGraff W, Hankovszky OH, Sar CP, Kalai T, Jeko J, Russo A, Mitchell JB, Hideg K. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J Med Chem 41:3477-3492, 1998.
229. Suy S, Mitchell JB, Ehleiter D, Haimovitz-Friedman A, Kasid U. Nitroxides tempol and tempo divergent signal transduction pathways in MDA-MB 231 breast cancer cells. J Biol Chem 273:17871-17878, 1998.
230. Krishna MC, Kuppusamy P, Afeworki M, Zweir J, Cook JA, Subramanian S, Mitchell JB. Development of functional paramagnetic resonance imaging. Breast Diseases, 10:209-220, 1998.
231. Wink DA, Vodovotz Y, Cook, JA, Krishna MC, Kim S, Coffin D, DeGraff W, DeLuca AM, Liebmann JE, Mitchell JB. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Moscow) 63:802-809, 1998.
232. Mitchell JB, DeGraff W, Kim S, Cook JA, Gamson J, Christodoulou D, Feelisch M, Wink DA. Redox generation of nitric oxide to radiosensitize hypoxic cells. Int J Radiat Oncol Biol Phys 42:795-798, 1998.

233. Hahn SM, DeLuca AM, Coffin D, Krishna CM, Mitchell JB. *In vivo* radioprotection and effects on blood pressure of the stable free radical nitroxides. Int J Radiat Oncol Biol Phys 42:839-842, 1998.
234. Dewhirst MW, Mitchell JB. Introduction: Tumor physiology and metastases. Semin Radiat Oncol 8:141-142, 1998.
235. Vodovotz, Y, Chan RC, DeGraff W, Chornenky VI, Mitchell JB, and Waksman R. Low energy x-radiation results in localized inhibition of V79 fibroblast cell proliferation consistent with dosimetry measurements: possible application for prevention of restenosis. Int. J. Cardiovasc. Interventions 1:41-4, 1998.
236. Mitchell JB. Radiation Biology Concepts for the use of radiation to prevent restenosis. In: Waksman R, Ed. Vascular Brachytherapy, Second Edition, Futura, Armonk, NY, 1999.
237. Samuni Y, Coffin D, DeLuca AM, DeGraff WG, Venson DJ, Ambudkar I, Chevion M, Mitchell JB. The use of Zn-desferrioxamine for radioprotection in mice, tissue culture, and isolated DNA. Cancer Res 59:405-409, 1999.
238. Hahn SM, Russo A, Cook JA, Mitchell JB. A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin. Int J Oncol 14:273-279, 1999.
239. Mitchell JB, Krishna MC, Samuni A, Russo A, Hahn SM. Nitroxides as protectors against oxidative stress. In: Gilbert DL, Colton CA, Eds. Reactive Oxygen Species in Biological Systems: An Interdisciplinary Approach. Kluwer Academic/Plenum, New York: 293-313, 1999.
240. Wink DA, Vodovotz Y, Grisham MB, DeGraff W, Cook J, Pacelli R, Krishna M, Mitchell JB. Antioxidant effects of nitric oxide. Methods Enzymol 301:413-424, 1999.
241. Coleman CN and Mitchell JB. Clinical Radiosensitization: Why it does and does not work. J Clin Oncol 17:1-3, 1999.
242. Subramanian S, Murugesan R, Devasahayam N, Cook JA, Afeworki M, Pohida T, Tschudin RG, Mitchell JB, Krishna MC. High-speed data acquisition system and receiver configurations for time-domain radiofrequency electron paramagnetic resonance spectroscopy and imaging. J Magn Reson 137:379-388, 1999.
243. Vodovotz Y, Coffin D, DeLuca AM, McKinney L, Cook JA, Wink D, Mitchell JB. Induction of nitric oxide production in infiltrating leukocytes following in vivo irradiation of tumor-bearing mice. Radiat Oncol Invest 7:86-97, 1999.
244. Hahn SM, Sullivan FJ, DeLuca AM, Bacher JD, Liebmann J, Krishna CM, Coffin D, Mitchell JB. Hemodynamic effect of the nitroxide superoxide dismutase mimics. Free Radic Biol Med 27:529-35, 1999.

245. Herscher LL, Cook JA, Pacelli R, Pass HI, Russo A, Mitchell JB. Principles of chemoradiation: Theoretical and practical considerations. Oncology, suppl 5:11-22, 1999.
246. Devasahayam N, Subramanian S, Murugesan R, Cook JA, Afeworki M, Tschudin RG, Mitchell JB, Krishna MC. Parallel coil resonators for time-domain radiofrequency electron paramagnetic resonance imaging of biological objects. J Magn Reson 142:168-176, 2000.
247. Bernhard EJ, Mitchell JB, Deen D, Cardell M, Rosenthal DI, Brown JM. Re-evaluating gadolinium III texaphyrin as a radiosensitizing agent. Cancer Res 60:86-91, 2000.
248. Afeworki M, van Dam, GM, Devasahayam N, Murugesan R, Cook J, Coffin D, Larsen JHA, Mitchell JB, Subramanian S, Krishna MC. Three-dimensional whole body imaging of spin probes in mice by time-domain radiofrequency electron paramagnetic resonance. Magn Reson Med 43:375-382, 2000.
249. Mitchell JB, Cook JA, Stein W, Coffin D, Espey, MG, Miranda KM, Wink DA. Is There a Role for Nitric Oxide in Cancer Treatment? Radiat Res Vol. 2, Congress Proceedings, Allen Press, Inc. pp. 618-621, 2000.
250. Hahn SM, Krishna MC, DeLuca AM, Coffin D, Mitchell JB. Evaluation of the hydroxylamine Tempol-H as an in vivo radioprotector. Free Radic Biol Med 28:953-958, 2000.
251. Rak R, Chao DL, Pluta RM, Mitchell JB, Oldfield EH, Watson JC. Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J Neurosurg 92:646-651, 2000.
252. Mitchell JB, Russo A, Kuppusamy P, Krishna MC. Radiation, radicals, and images. Ann N Y Acad Sci 899:28-43, 2000.
253. Vodovotz Y, Lucia MS, DeLuca AM, Mitchell JB, Kopp JB. Reduced hematopoietic function and enhanced radiosensitivity of transforming growth factor-beta1 transgenic mice. Int J Cancer 90:13-21, 2000.
254. Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler-Stevenson M, Ashkenazi A, Steeg PA. Radiation and the Apo2 ligand apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Research 60: 2611-2615, 2000.
255. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, Mitchell JB, Van Waes C. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF- κ B. Head & Neck 22: 748-759, 2000.
256. Kosceilniak J, Devasahayam N, Moni MS, Kuppusamy P, Yamada K, Mitchell JB, Krishna MC Subramanian S. 300 MHz continuous wave electron paramagnetic resonance

- spectrometer for small animal in vivo imaging. *Review of Scientific Instruments* 71: 4273-4281, 2000.
257. Vodovotz Y, Waksman R, Cook JA, Kim WH, Chan R, Seabron R, Collins SD, Pierre A, Bramwell O, Wink D, Mitchell JB, Leon M. S-nitrosoglutathione reduces non-occlusive thrombosis rate following balloon overstretch injury and intracoronary irradiation of porcine coronary arteries. *Int. J. Radiat. Oncol. Biol. Phys.* 48: 1167-1174, 2000.
258. Wink DA, Miranda KM, Espey MG, Mitchell JB, Grisham MB, Fukuto J, Feelish M. The chemical biology of NO. Balancing NO with oxidative and nitrosative stress. (ed. Mayer B,) In "Handbook of Experimental Pharmacology," Springer-Verlag, Berlin, 7-32, 2000.
259. Wink DA, Vodovotz Y, DeGraff W, Cook JA, Pacelli R, Krishna MC, Mitchell JB. Protective effects of NO against oxidative injury. (ed. Fang F) In "Nitric Oxide and Infection," Plenum Press NY, 2000.
260. Vodovotz Y, Mitchell JB, Lucia MS, McKinney L, Kollum M, Cottin Y, Chan RC, Barcellos-Hoff MH, Waksman R. Modulation of protein expression and activity by radiation: Relevance to intracoronary radiation for the prevention of restenosis. *Cardiovascular Radiation Medicine*. 1:4 336-343, 2000
261. Mitchell JB, Krishna MC, Samuni A, Kuppusamy P, Hahn SM, Russo A. Clinical use of Nitroxides as superoxides-dismutase mimics. In: Rhodes CJ, ed. Toxicology of the Human Environment - The Critical Roll of Free Radicals. London and New York: Taylor & Francis, 113-138, 2000.
262. Samuni Y, DeGraff W, Chevion M, Mitchell JB, Cook JA. Radiation sensitization of mammalian cells by metal chelators. *Radiat. Res.* 155: 304-310, 2001.
263. Ling CC, Mitchell JB. Introduction: Functional imaging and its application to radiation oncology. *Seminars in Radiation Oncology* 11: 1-2, 2001.
264. Sunwoo JB, Herscher LL, Kroog GS, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S, Figg WD, Cook JA, Mitchell JB, Van Waes C. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. *J. Clin. Oncol.* 19: 800-811, 2001.
265. Ogawa R, Pacelli R, Espey MG, Miranda KM, Friedman N, Kim SM, Cox G, Mitchell JB, Wink DA, Russo A. Comparison of control of Listeria by nitric oxide redox chemistry from murine macrophages and NO donors: insights into Listeriocidal activity of oxidative and nitrosative stress. *Free Radic. Biol. Med.* 30: 268-276, 2001.
266. Krishna MC, Devashayam N, Cook JA, Subramanian S, Kuppusamy P, Mitchell JB. Electron paramagnetic resonance for small animal imaging applications. *ILAR* 42: 209-218. 2001.

267. Krishna MC, Subramanian S, Kuppusamy P, Mitchell JB. Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Sem. Radiat. Oncol 11 (1): 58-69, 2001.
268. Samuni AM, DeGraff W, Krishna MC, Mitchell JB. Cellular sites of H₂O₂-induced damage and their protection by nitroxides. Biochimica et Biophysica Acta 1525: 70-76, 2001.
269. Samuni AM, Afeworki M, Stein W, Yordanov AT, DeGraff W, Krishna MC, Mitchell JB Brechbiel MW. Multifunctional antioxidant activity of HBED iron chelator. Free Radic Biol Med 30: 170-177, 2001.
270. Roberts AB, Piek E, Böttinger E, Ashcroft G, Mitchell JB, Flanders K. Smad3-a major player in signal transduction pathways leading to fibrogenesis? Chest 120: S43-S47, 2001
271. Yordanov AT, Yamada K, Krishna MC, Mitchell JB, Woller E, Cloninger M, Brechbiel MW. Spin-labeled dendrimers in EPR imaging with low molecular weight nitroxides. Chem. Int.Ed. 40 (14): 2690-2692, 2001
272. Mitchell JB, Krishna MC, Kuppusamy P, Cook JA, Russo A. Protection against oxidative stress by nitroxides. Exp Biol Med. 226 (7): 620-621, 2001.
273. Coleman CN, Mitchell JB. Radiation Modifiers. In: Chabner BA, Longo DA, Eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott, Williams, & Wilkins, pp. 707-751, 2001.
274. Cook JA, Mitchell JB. Predictive assays for radiation oncology. In: Joslin CAF, Flynn A, Hall EJ, Ed. Principles and Practice of Brachtherapy. London: Arnold, pp. 205-214, 2001.
275. Poggi MM, Coleman CN, Mitchell JB. Sensitizers and protectors of radiation and chemotherapy. Curr. Probl. Cancer 25: 334-412, 2001.
276. Kuppusamy P, Li H, Ilangovan G, Cardouni AJ, Zweier JL, Yamada K, Krishna MC, Mitchell JB. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 62: 307-312, 2002.
277. Coleman CN, Mitchell JB, Camphausen K. Tumor hypoxia: chicken, egg, or a piece of the farm? J. Clin. Oncol. 20: 610-615, 2002.
278. Krishna MC, English S, Yamada K, Yoo J, Murugesan R, Devasahayam N, Cook JA, Golman K, Ardenkjær-Larsen JH, Subramanian S, Mitchell JB. Overhauser enhanced magnetic resonance imaging for tumor oximetry: Coregistration of tumor anatomy and tissue oxygen concentration. Proc. Natl. Acad. Sci. 99 (4):2216-2221, 2002.
279. Mitchell JB and Krishna MC. Nitroxides as radiation protectors. Military Medicine, 167: 49-50, 2002.

280. Yamada K-I, Murugesan R, Devasahayam N, Cook JA, Mitchell JB, Subramanian S, Krishna MC. Evaluation and comparison of pulsed and continuous wave radiofrequency electron paramagnetic resonance techniques for *in vivo* detection and imaging of free radicals. J Magn Reson. 154: 287-297, 2002.
281. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160: 1057-1068, 2002.
282. Subramanian S, Yamada KI, Irie A, Murugesan R, Cook JA, Devasahayam N, Van Dam GM, Mitchell JB, Krishna MC. Noninvasive *in vivo* oximetric imaging by radiofrequency FT EPR. Magn. Reson. Med. 47: 1001-1008, 2002.
283. Yordanov AT, Yamada K, Krishna MC, Russo A, Yoo J, English S, Mitchell JB, Brechbiel MW. Acyl-protected hydroxylamines as spin label generators for EPR brain imaging. J. Med. Chem. 45: 2283-2288, 2002.
284. Goldstein S, Samuni A, Aronovitch Y, Godinger D, Russo A, Mitchell JB, Kinetics of paraquat and copper reactions with nitroxides: the effects of nitroxides on the aerobic and anoxic toxicity of paraquat. Chem. Res. Toxicol. 15: 686-691, 2002.
285. Miranda KM, Yamada K, Espey MG, Thomas DD, DeGraff W, Mitchell JB, Krishna MC, Colton CA, Wink DA. Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch. Biochem. Biophys. 401: 134-144, 2002.
286. Chandrasekharan S, Qiu TH, Alkharouf N, Brantley K, Mitchell JB, Liu ET. Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Mol. Cell. Biol. 22: 5235-5247, 2002.
287. Samuni AM, Krishna MC, DeGraff W, Russo A, Planalp RP, Brechbiel MW, Mitchell JB. Mechanisms underlying the cytotoxic effects of Tachpyr-a novel metal chelator. Biochim. Biophys. Acta 1571: 211-218, 2002.
288. Samuni AM, DeGraff W, Krishna MC, Mitchell JB. Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity. Mol. Cell. Biochem. 234/235: 327-333, 2002.
289. Samuni A, Goldstein S, Russo A, Mitchell JB, Krishna MC, Neta P. Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. J. Am. Chem. Soc. 124: 8719-8724, 2002.
290. Yamada KI, Kuppusamy P, English S, Yoo J, Irie A, Subramanian S, Mitchell JB, Krishna MC. Feasibility and assessment of non-invasive *in vivo* redox status using electron paramagnetic resonance imaging. Acta Radiol. 43: 433-440, 2002.
291. Ilangovan G, Li H, Zweier JL, Krishna MC, Mitchell JB, Kuppusamy P. *In vivo* measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: effect of carbogen-breathing. Magn. Reson. Med. 48: 723-730, 2002.

292. Xavier S, Yamada K, Samuni AM, Samuni A, DeGraff W, Krishna MC, Mitchell JB. Differential protection by nitroxides and hydroxylamines to radiation-induced and metal ion-catalyzed oxidative damage. Biochim. Biophys. Acta 1573: 109-120, 2002.
293. Poggi MM, Kroog GS, Russo A, Muir C, Cook J, Smith J, Mitchell JB, Herscher LL. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 54: 670-676, 2002.
294. Chuang YE, Chen Y, Chandramouli GVR, Cook JA, Coffin D, Tsai MH, DeGraff W, Yan H, Zhao S, Russo A, Liu ET, Mitchell JB. Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 62: 6246-6254, 2002.
295. Murugesan R, English S, Reijnders K, Yamada K, Cook JA, Mitchell JB, Subramanian S, Krishna MC. Fluorine electron double resonance imaging for ¹⁹F MRI in low magnetic fields. Magn. Reson. Med. 48(3): 523-9, 2002.
296. Mitchell JB, Xavier S, DeLuca AM, Sowers AL, Cook JA, Krishna MC, Hahn SM, Russo A. A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic. Biol. Med. 34: 93-102, 2003.
297. Stein W, Subramanian S, Mitchell JB, Krishna MC. EPR imaging of vascular changes in oxygen in response to carbogen breathing. Adv. Exp. Med. Biol. 510: 231-236, 2003.
298. Hu G, Lyeth BG, Zhao X, Mitchell JB, Watson JC. Neuroprotection by the stable nitroxide 3-carbamoyl-proxyl during reperfusion in a rat model of transient focal ischemia. J. Neurosurg. 98: 393-396, 2003.
299. Wink DA, Mitchell JB. Nitric oxide and cancer: an introduction. Free Radic. Biol. Med. 34: 951-954, 2003.
300. Samuni A, Chuang E, Krishna MC, Stein W, DeGraff W, Russo A, Mitchell JB. Semiquinone radical intermediate in catecholic estrogen-mediated cytotoxicity and mutagenesis: chemoprevention strategies with antioxidants. Proc. Natl. Acad. Sci. USA 100: 5290-5395, 2003.
301. Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN. Development of Radiation Modifiers. J. Natl. Cancer Inst. 95: 646-651, 2003.
302. Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat. Res. 159: 812-834, 2003.

303. Kennedy CH, Pass HI, Mitchell JB. Expression of human MutT homologue (hMTH1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue. Free Radic. Biol. Med. 34:1447-1457, 2003.
304. DeGraff WG, L. S. Myers LS Jr, Mitchell JB, Hahn SM. Protection against Adriamycin® cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid. Int J Oncol 23: 159-163, 2003.
305. Yordanov AT, Kobayashi H, English SJ, Reijnders K, Milenic D, Krishna MC, Mitchell JB, and Brechbiel MW. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. J Materials Chem 13: 1523-1525, 2003.
306. Taube AG, Subramanian S, Murugesan R, Devasahayam N, Mitchell JB, Krishna MC, Cook JA. An application system for automation of constant-time radio frequency electron paramagnetic resonance imaging. Comput Methods Programs Biomed. 72: 127-138, 2003.
307. Flanders KC, Major CD, Arabshahi A, Aburime EE, Okada MH, Fujii M, Blalock TD, Schultz GS, Sowers A, Anzano MA, Mitchell JB, Russo A, and Roberts AB. Interference with transforming growth factor- β /Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am J Pathol 163: 2247-2257, 2003.
308. Bisht KS, Bradbury CW, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, and Gius D. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the *in vitro* and *in vivo* radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63: 8984-8995, 2003.
309. Reijnders K, English SJ, Krishna MC, Cook JA, Sowers AL, Mitchell JB, Zhang, Y. Influence of body temperature on the BOLD effect in murine SCC tumors. Magn Reson Med 51: 389-393, 2004.
310. Vitolo JM, Cotrim AP, Sowers AL, Russo A, Wellner RB, Pillemer SR, Mitchell JB, Baum BJ. The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 10: 1807-1812, 2004. (Article Highlighted in Journal)
311. Xavier S, Pike E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni A, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A. Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor- β signaling by halofuginone. J Biol Chem 279: 15167-15176, 2004.
312. Devasahayam N, Murugesan R, Matsumoto K, Mitchell JB, Cook JA, Subramanian S, Krishna MC. Tailored sinc pulses for uniform excitation and artifact-free radio frequency time-domain EPR imaging. J Magn Reson 168: 110-117, 2004.

313. Samuni Y, Gamson J, Samuni A, Yamada K, Russo A, Krishna MC, Mitchell JB. Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid Redox Signal 6: 587-95, 2004.
314. Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Harris AL, Huang E, Johnson R, Kaelin W Jr, Koch CJ, Maxwell P, Mitchell J, Neckers L, Powis G, Rajendran J, Semenza GL, Simons J, Storkebaum E, Welch MJ, Whitelaw M, Melillo G, Ivy SP. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 64: 3350-3356, 2004.
315. Ralf Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, Russo A, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant Tempol in *Atm*-deficient mice. Hum Mol Genet 13: 1793-1802, 2004.
316. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, and Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Seminars in Radiat Oncol 14: 259-266, 2004.
317. Matsumoto KI, Krishna MC, Mitchell JB. Novel pharmacokinetic measurement using electron paramagnetic resonance spectroscopy and simulation of in vivo decay of various nitroxyl spin probes in mouse blood. J Pharmacol Exp Ther 310: 1076-1083, 2004.
318. Van Waes C, Sunwoo JB, DeGraff W, Mitchell JB. Radiosensitization and proteasome inhibition, in Adams J, ed., Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy, pp 123-131, Humana Press, Totowa, NJ, 2004.
319. Samuni AM, Degraff W, Cook JA, Krishna MC, Russo A, Mitchell JB. The effects of antioxidants on radiation-induced apoptosis pathways in TK6 cells. Free Radic Biol Med 37: 1648-1655, 2004.
320. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bisht KS, Ho AS, Mattson D, Sun L, Munson PJ, Chuang EY, Mitchell JB, Feinberg AP. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6:361-71, 2004.
321. Matsumoto K, English S, Yoo J, Yamada K, Devasahayam N, Cook JA, Mitchell JB, Subramanian S, Krishna MC. Pharmacokinetics of a triarylmethyl-type paramagnetic spin probe used in EPR oximetry. Magn Reson Med 52: 885-92, 2004.
322. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegan J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell JB, Baldwin AS Jr, Van Waes C. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64: 6511-23, 2004.
323. Subramanian S, Matsumoto K, Mitchell JB, Krishna MC. Radio frequency continuous-wave and time-domain EPR imaging and Overhauser-enhanced magnetic resonance imaging of small animals: instrumental developments and comparison of relative merits for functional imaging. NMR Biomed 17: 263-94, 2004.

324. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM. Fludarabine Treatment of Chronic Lymphocytic Leukemia Patients Induces a p53-Dependent Gene Expression Response. Blood 104: 1428-34, 2004.
325. Metz JM, Smith D, Mick R, Lustig R, Mitchell J, Cherukuri M, Glatstein E, and Hahn SM. A phase I study of Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 10: 6411-6417, 2004.
326. Mitchell JB, Yamada K, Devasahayam N, Cook JA, Subramanian S, Krishna MC. Novel functional imaging for tissue oxygen concentration and redox status. J Nutr 134: 3210S, 2004.
327. Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, Brechbiel MW. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 10: 7712-7720, 2004.
328. Samuni AM, Kasid U, Chuang EY, Suy S, William DeGraff W, Krishna MC, Russo A, Mitchell JB. Effects of hypoxia on radiation-responsive stress-activated protein kinase, p53, and caspase 3 signals in TK6 human lymphoblastoid cells. Cancer Res 65: 579-86, 2005.
329. Tsai MH, Yan H, Chen X, Chandramouli GV, Zhao S, Coffin D, Coleman CN, Mitchell JB, Chuang EY. Evaluation of hybridization conditions for spotted oligonucleotide-based DNA microarrays. Mol Biotechnol 29: 221-224, 2005.
330. Suy S, Mitchell JB, Samuni A, Mueller S, Kasid U. Nitroxide tempo, a small-molecule, induces apoptosis in prostate cancer cells and suppresses tumor growth in athymic mice. Cancer 103: 1302-1313, 2005.
331. Matsumoto K, Okajo A, Kobayashi T, Mitchell JB, Krishna MC, Endoa K. Estimation of free radical formation by β -ray irradiation in rat liver. J Biochem Biophys Methods 63: 79-90, 2005.
332. Erker L, Schubert R, Yakushiji H, Barlow C, Larson D, Mitchell JB, Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor. Hum Mol Genet 14: 1699-1708, 2005.
333. Muanza TM, Cotrim AP, McAuliffe M, Sowers AL, Baum BJ, Cook JA, Feldchtein F, Amazeen P, Coleman CN, Mitchell JB. Evaluation of radiation-induced oral mucositis by Optical Coherence Tomography. Clin Cancer Res 11: 5121-5127, 2005. (Article Highlighted in Journal)
334. Camphausen K, Citrin D, Krishna MC, Mitchell JB. *Editorial: Implications for tumor control during protection of normal tissues with antioxidants.* J Clin Oncol 23: 5455-5457, 2005.

335. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Med 102: 13604-13609, 2005.
336. Cotrim AP, Sowers AL, Lodde BM, Vitolo JM, Kingman A, Russo A, Mitchell JB, Baum BJ. Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model. Clin Cancer Res 11: 7564-7568, 2005.
337. Tsai M-H, Chen X, Chandramouli GVR, Chen Y, Yan H, Zhao S, Keng P, Liber HL, Coleman CN, Mitchell JB, Chuang EY. Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene 2005.
338. Matsumoto A, Matsumoto S, Sowers AL, Koscielniak JW, Trigg NJ, Kuppusamy P, Mitchell JB, Subramanian S, Krishna MC, Matsumoto KI. Absolute oxygen tension (pO₂) in murine fatty and muscle tissue as determined by EPR. Magn Reson Med 54: 1530-1535, 2005.
339. Sostaric JZ, Miyoshi N, Riesz P, DeGraff WG, Mitchell JB. N-alkyl glucopyranosides completely inhibit ultrasound-induced cytotoxicity. Free Radic Biol Med 39: 1539-1548, 2005.
340. Patel K, Chen Y, Dennehy K, Blau J, Connors S, Mendonca M, Tarpey M, Krishna MC, Mitchell JB, Welch WJ, Wilcox CS. Acute antihypertensive action of nitroxides in the spontaneously hypertensive rat. Am J Physiol Regul Integr Comp Physiol 290: R37-R43, 2006.

IN PRESS

Baum BJ, Zheng C, Cotrim AP, Goldsmith CM, Atkinson JC, Brahim JS, Chiorini JA, Voutetakis A, Leakan RA, Van Waes C, Mitchell JB, Delporte C, Wang S, Kaminsky SM, Illei

GG. Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochim Biophys Acta 2005.

PATENTS:

1. Mitchell JB, Samuni A, DeGraff WG, Hahn SM. "Nitroxides as protectors against oxidative stress." U.S. Patent No. 5,462,946, Issued October 31, 1995.
2. Bourg J, Mitchell JB, Mirotznik M, Roth B, Subramanian S, Krishna MC, Zablocky P. "Pulsed low-frequency EPR spectrometer and Imager." Patent No. 5,387,867 Issued February 7, 1995.
3. Bourg J, Mitchell JB, Mirotznik M, Roth B, Subramanian S, Krishna MC, Zablocky P, Pohida TJ, Smith PD, Friauf WS, Tschudin RG. "Pulsed low-frequency EPR spectrometer and Imager." Patent No. 5,502,386 Issued March 26, 1996.
4. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE. "Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers." U.S. Patent No. 5,650,442, Issued July 22, 1997.
5. Wink DA, Mitchell JB, Russo A, Krishna MC, Hanbauer I, Grisham MB, Granger DN. "Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury." U.S. Patent No. 5,789,447, Issued August 4, 1998.
6. Murugesan R, Tschudin R, Subramanian S, Mitchell JB, Krishna MC. "System and method for performing *in vivo* imaging and oxymetry by pulsed electron paramagnetic resonance." Serial No. 08/504,616. Filed 8/25/95. U.S. Patent No. Issued July, 1997.
7. Tschudin R, Murugesan R, Subramanian S, Mitchell JB, Krishna MC. "Gated radiofrequency amplifier." DHHS Reference No. E-175-96/1. Filed 8/96. Allowed: March, 1997.
8. Mitchell JB, Russo A, Krishna MC, DeGraff W, DeLuca AM, Myers L, Hahn S. Benzoates as protectors against oxidative stress and chemotherapy drug toxicity. Filed with U.S. Patent Office, March 20, 1997.

9. Mitchell JB, Russo A, Krishna MC, Wink DA, Liebmann JE. "Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers." U.S. Patent No. 5,814,667, Issued September 29, 1998.
10. Mitchell, JB, Russo, A, Krishna, MC, Wink, DA, Liebmann, JE. "Use of nitric oxide-releasing compounds to sensitize cancerous cells to chemotherapeutic agents." U.S. Patent No. 5,837,736, Issued November 17, 1998.
11. Tschudin, RG, Murugesan, R, Cherukuri, MK, Mitchell, JB, Subramanian, S. "Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI." U.S. Patent No. 5,828,216, Issued October 27, 1998.
12. Mitchell, JB, Russo, A, Krishna, MC, Wink, WA, Liebmann, JE. "Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents." U.S. Patent No. 5,840,759, Issued November 24, 1998.
13. Murugesan R, Cherukuri MK, Mitchell JB, Subramanian S, Tschudin R. "In vivo imaging and oxymetry by pulsed radiofrequency paramagnetic resonance." U.S. Patent No. 5,865,746, Issued February 2, 1999.
14. Devasahayam N, Mitchell JB, Russo A, Cook JA, Afeworki M, Tschudin R, Subramanian S, Murugesan R, Harrington F, Cherukuri MK. "Resonant structure for spatial and spectral-spatial imaging of free radical spin probes using radiofrequency time domain electron paramagnetic resonance spectroscopy." DHHS Reference No. E-166-97/0, filed May 27, 1997. Allowed February 1998.
15. Roberts AB, Ashcroft GS, Russo A, Mitchell JB. "Inhibition of SMAD3 to prevent fibrosis and improve wound healing." DHHS Reference No. 10/299,886, filed November 18, 2002, Pending.
16. Mitchell JB, Samuni A, DeGraff WG, Hahn SM. "Nitroxides as protectors against oxidative stress." Patent No. 6,605,619 Issued August 12, 2003. (CIP of Patent No. 5,462,946 Issued October 31, 1995)
17. Mitchell JB, et al. "The use of nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer." DHHS Reference No. E-167-1997/0-US-07, filed March 3, 2000, US Patent Application No. 09/424,519.

INVITED PRESENTATIONS:

1. Dose-rate effects in mammalian cells. Department of Radiation Therapy, University of Arizona, Tucson, Arizona, January, 1980.
2. Effects of varying dose-rate on the mammalian cell cycle. Cytogenetics Branch, Oak Ridge National Laboratory, Oak Ridge, Tennessee, March, 1980.
3. Dose-rate effects in plateau phase mammalian cells. Department of Radiation Therapy, Southwestern Medical School, Dallas, Texas, May, 1980.
4. The radiation response of Ewing's sarcoma tumor cells and CFUc from patients receiving IV BUdR. Department of Radiation Therapy, George Washington University Hospital, Washington, D.C. May, 1982.
5. Invited Symposium Speaker: Thiols and Thermal Sensitivity. Radiation Research Society Meeting in San Antonio, Texas, March, 1983.
6. The role of glutathione and thermal sensitivity. Gray Laboratory, Northwood, England, July, 1983.
7. The role of glutathione in the cellular response to radiation and selected chemotherapy drugs. Physiology Branch, Armed Forces Radiobiological Research Institute, Bethesda, Maryland, October, 1983.
8. Clinical radiobiology developments at NIH. Mid-Atlantic Chapter of American Association of Physicists in Medicine. Bethesda, Maryland, February, 1984.
9. Invited Symposium Speaker: The *in vitro* radiobiology of human lung cancer. Workshop on Radiotherapy for Lung Cancer. The International Association for the Study of Lung Cancer. King's College, Cambridge, England, June, 1984.
10. Invited Keynote Speaker: The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy. Chemical Modifiers of Cancer Treatment, Clearwater, Florida, October, 1985.
11. Invited Lecturer: The importance of cellular glutathione in the radiation and chemotherapy response. University of Rochester Cancer Center, Rochester, New York, November, 1985.
12. Invited Lecturer: Cellular and Molecular properties of human lung cancer cell lines and their relationship to radiation sensitivity. Annual meeting of the Radiological Society of North America, Chicago, Illinois, November, 1985.
13. Invited Lecturer: The role of glutathione in the radiation and chemotherapy response of human lung cancer cells. Thomas Jefferson University Hospital, Philadelphia, PA. January, 1986.

14. Invited Speaker: Modification of chemotherapy response by cellular thiol modulation. Symposium, Cellular Effects of Thiol Modulation: Radiation, Hyperthermia, and Chemotherapy, 34th Annual Radiation Research Society Meeting, Las Vegas, Nevada, April 1986.
15. Invited Speaker: The role of glutathione in radiation and drug induced cytotoxicity. 13th L.H. Gray Conference, Free Radical Biochemistry and Radiation Injury, Brunel University, London, United Kingdom, July, 1986.
16. Invited Speaker: Photodynamic Therapy of Human Ascites. Australian Phototherapy Conference, Ludwig Cancer Institute, Royal Melbourne Hospital, Melbourne, October 1986.
17. Invited Speaker: Role of Glutathione and Other Endogenous Thiols in Radiation Protection. Symposium on Perspectives in Radioprotection, Armed Forces Radiobiology Research Institute. Bethesda, Maryland, March, 1987.
18. Invited Speaker: Glutathione Levels as a Predictor of Cell Response to Drugs and Radiation. Conference on Prediction of Tumor Treatment Response. Banff, Canada. April, 1987.
19. Invited Speaker: Comparison of Misonidazole Hypoxic Cytotoxicity Between Cell Lines with Different Intracellular Glutathione Levels and the Influence of Thiol Modulation on the Chemotherapy and Radiation Response. Eight International Congress of Radiation Research, Edinburgh Scotland, July, 1987.
20. Invited Speaker: "Biological considerations of dose rate effects." First Biennial Brachytherapy and Remote Afterloading Symposium and Workshop. Mallinckrodt Institute of Radiology. St. Louis, Missouri, September 1987.
21. Invited Speaker: "Are chemoresistant cells radioresistant?" Second International Head and Neck Oncology Research Conference. Arlington, Virginia, September 1987.
22. Refresher Course "Radiobiology and Clinical Radiation Therapy: Mechanisms of Repair". 1987 ASTRO meeting. Boston, Massachusetts. October, 1987.
23. Invited Speaker: Scientific Session: Cellular and Molecular Properties of Human Lung Cancer Cell Lines. Radiation Therapy Oncology Group, New Orleans, Louisiana, January, 1988.
24. Invited Cancer Center Speaker: Glutathione as a Predictor of Tumor Response? Yale University. New Haven, Connecticut, January, 1988.
25. Invited Keynote Speaker: Glutathione Modulation in Cancer Treatment: Will it work? Clinical Modifiers of Cancer Treatment. Paris, France. March, 1988.
26. Workshop Chairman: Hyperthermia and Oxidative Stress. Eight Annual Meeting of the North America Hyperthermia Group. Philadelphia, Pennsylvania April, 1988.

27. Invited Speaker: Bioclinical Conference, Glutathione modulation and cancer treatment. Washington University School of Medicine. St. Louis, Missouri May, 1988.
28. Invited Speaker: Department of Biochemistry Rounds: Glutathione Modulation and Cancer Treatment. University of Pennsylvania. Philadelphia, Pennsylvania, June, 1988.
29. Invited Speaker. Biological Basis of Low and High Dose Rate Brachytherapy. The VIII Brachytherapy Update 1988. Memorial Sloan-Kettering Cancer Center. New York, New York, September, 1988.
30. Invited Speaker: Refresher Course "Radiobiology and Clinical Radiation Therapy: Mechanisms of Repair". 1988 ASTRO meeting. New Orleans, Louisiana October, 1988.
31. Invited Speaker: "The Radiobiology and Clinical Application of Halogenated Pyrimidine Radiosensitizers" 15th L.H. Gray Conference, University of Kent, Canterbury, England, April, 1989.
32. Invited Speaker: "Halogenated Pyrimidine Radiosensitizers," University of Maryland Cancer Center Grand Rounds, Baltimore, Maryland, June, 1989.
33. Invited Speaker: "The Role of Glutathione in Drug and Radiation Response" International Congress of Radiology, Paris, France, July, 1989.
34. Invited Speaker: "Nitroxides as Superoxide Dismutase Mimics," Cancer Center Grand Rounds, University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, July, 1989.
35. Invited Speaker: Refresher Course: "Radiobiology and Clinical Radiation Therapy: Mechanisms of Repair". 1989 ASTRO meeting. San Francisco, California, October, 1989.
36. Invited Speaker: "Glutathione Modulation and Cancer Treatment," 6th Annual Y.H. Lee Lecture, Department of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota., November, 1989.
37. Invited Speaker: "Oxygen Free Radicals and Cancer Treatment." Oxygen Club of Washington, November, 1989.
38. Invited Speaker: "Nitroxide Free Radicals as Protectors against Oxidative Stress." Radiation Oncology Rounds. Henry Ford Hospital, Detroit, Michigan, May, 1991.
39. Invited Speaker: "New Radiation Protectors," Radiation Oncology Rounds, University of Pennsylvania, Philadelphia, Pennsylvania, May, 1991.
40. Invited Speaker: "The Issue of Cross Resistance Between Chemotherapy and Radiation." Educational Program of the American Society of Clinical Oncology. Twenty-seventh Annual Meeting of the American Society of Clinical Oncology, Houston, Texas, May 1991.

41. Invited Speaker: "Nitroxides as Protectors Against Oxidative Stress," New Developments in Free Radical Research - Prospects for new drugs. International Business Communications, Philadelphia, Pennsylvania, June, 1991.
42. Invited Symposium Speaker: "Prospects for Modifying the Radiosensitivity of Oxidative Tumor Cells." Radiobiology of Human Tumor Cells Symposium. 9th International Congress Radiation Research, Toronto, Canada, July, 1991.
43. Invited Symposium Speaker: "Nitroxides as Protectors Against Oxidative Stress." Third International Symposium on Spin Trapping and Aminoxy Radical Chemistry. Kyoto, Japan, November 1991.
44. Invited Symposium Speaker: "Protectors Against Oxidative Stress." 40th Annual Meeting of the Radiation Research Society, Salt Lake City, Utah, March 1992.
45. Invited Symposium Speaker: "Nitroxide Protection Against the Hypoxic Cytotoxicity of Mitomycin C and SR-4233." Biochemicals Workshop, Oxford, England, September 1992.
46. Invited Debator: "This House Believes that Current Assays for Radiosensitivity Have no Role to Play in Predicting Radiotherapy Outcome." Third Annual Painter Debate, 41st Annual Meeting of the Radiation Research Society, Dallas, Texas, March 1993.
47. Invited Speaker: "Potential Use of Nitroxides in Radiation Oncology." 4th International Conference on Anticarcinogenesis and Radiation Protection, Baltimore, Maryland, April 1993.
48. Invited Speaker: "Radiobiological considerations in radionuclide therapy." 40th Annual Meeting of the Society of Nuclear Medicine/Radiopharmaceutical Science Council, Toronto, Ontario, Canada, June 1993.
49. Invited Speaker: "Taxol-mediated G2/M cell cycle blocks and radiosensitization: differences among human tumor cell types." 8th International Conference on Chemical Modifiers, Kyoto, Japan, June 1993.
50. Invited Speaker: "Modifying the aerobic response to radiation and cytotoxic drugs." International Congress of Radiation Oncology/Kyoto '93 Meeting, Kyoto, Japan, June 1993.
51. Invited Symposium Speaker: "Recent advances in the use of radioprotectors." Semi Annual Meeting of the Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, July 1993.
52. Invited Symposium Speaker: "New directions for free radical cancer research and medical applications." International Symposium: Free Radicals in Diagnostic Medicine University of New York at Buffalo, Buffalo, New York, October 1993.
53. Invited Speaker: "Fight a radical with a radical." The Joint Center for Radiation Therapy's Cancer Biology Division Seminar Series, Harvard Medical School, Boston, Massachusetts, December 1993.

54. Invited Speaker: "Radioprotection by free radicals." Radiation Protection and Radiation Recovery Research Program, University of Arkansas, Little Rock, Arkansas, February 1994.
55. Invited Speaker: "Fight a radical with a radical." Radiation Oncology Department, University of Pennsylvania, Philadelphia, PA, June 1994.
56. Invited Speaker: "Free radicals as protectors against oxidative stress." Radiation Oncology Department, Johns Hopkins Medical School, Baltimore, MD June 1994.
57. Invited Speaker: "The use of taxol as a radiation modifier." Chemoradiation Summit Meeting, Cancer Center at St. Agnes, Fresno, CA, September 1994.
58. Invited Speaker: "Free radicals as radioprotectors." ASTRO, San Francisco, CA, October 1994.
59. Invited Speaker: "Free radicals as protectors against oxidative stress." Anti-Oxidants, Oxidants, and Free Radicals, National Library of Medicine, National Institutes of Health, Bethesda, MD, December 1994.
60. Invited Speaker/Workshop Chair: "Nitric oxide and cancer treatment." Annual Meeting of the Radiation Research Society, San Jose, CA, April 1995.
61. Presentation: "Radiation sensitization by nitric oxide releasing agents." Ninth International Conference on Chemical Modifiers of Cancer Treatment, Oxford, England, August 1995.
62. Presentation: "Modulation of radiation-induced cytotoxicity by the nitric oxide releasing agent S-nitrosoglutathione (GSNO)." 10th International Congress on Radiation Research, Wurzburg, Germany, August 1995.
63. Invited Speaker: "Chemotherapy and radiation interactions." Fifth Biennial Meeting of the International Gynecological Cancer Society, Philadelphia, PA, September 1995.
64. Invited Speaker: "Chemical radiation sensitizers and protectors and normal tissue and tumor physiology." ASTRO, Miami, FL, October 1995.
65. Invited Speaker: "Nitroxides as protectors against oxidative stress." 44th Annual Meeting of the Radiation Research Society, Chicago, IL, April 1996.
66. Invited Speaker: "Free radicals as modulators of cancer treatment modalities." Grand Rounds, Duke University Medical Center, Durham, NC, November 1996.
67. Invited Speaker. "Free radicals as modulators of cancer treatment modalities." Laboratory of Biochemistry and Cell Signaling, NHLBI, NIH, January 1997.
68. Invited Symposium Speaker: "Dose, dose rate, and fractionation for vascular radiobiology." Advances In Cardiovascular Radiation Therapy, Washington, DC, February, 1997.

69. Invited Symposium Speaker: "Radioprotectant Therapies." Symposium: Radiation-Induced Xerostomia in Cancer Patients: Current Treatments and Future Therapies. International Association for Dental Research, Orlando, FL, March 1997.
70. Invited Symposium Speaker: "Nitric Oxide as a Modulator of Cancer Treatment Modalities." Symposium: Nitric Oxide: It's Role in Tumor Biology. Forty-fifth Annual Meeting of the Radiation Research Society, Providence, Rhode Island, May 1997.
71. Invited Workshop Speaker: "Imaging of Nitroxides in vivo." Workshop: Oxidative Stress and the Cellular Responses to Cancer Therapy. Forty-fifth Annual Meeting of the Radiation Research Society, Providence, Rhode Island, May 1997.
72. Invited Speaker: "Fourier Transform EPR Imaging" National Cancer Advisory Board, NIH, Bethesda, MD, June 1997.
73. Invited Speaker: "ESR Using Nitroxides to Study Free Radical Generation." Phase I Meeting Noninvasive Imaging Methods: Applications for Pharmacology, Therapeutics Development and Tumor Evaluation. NIH, Bethesda, MD September 1997.
74. Invited Speaker: "Nitroxides as Protectors Against Oxidative Stress." 10th Oxygen Radicals in Biology Gordon Research Conference, Ventura, CA, February 1998.
75. Invited Symposium Speaker: "Dose, Dose Rate and Radiation Sensitizers for Vascular Radiobiology." Advances in Cardiovascular Radiation Therapy II, Washington, DC, March 1998.
76. Invited Symposium Speaker: "Hyperthermia and Oxidative Stress Revisited," Symposium: Role of Oxidative Stress in Biological Responses to Heat Shock. Forty-sixth Annual Meeting of the Radiation Research Society & the Seventeenth Annual Meeting of the North American Hyperthermia Society, Louisville, KY, April, 1998.
77. Invited Visiting Professor: "Oxidative Stress, Protection, and Imaging of Free Radicals," Grand Rounds, Department of Radiation Oncology, University of Maryland, School of Medicine, Baltimore, Maryland, May, 1998.
78. Invited Speaker. "Radiation, Radicals, and Images." Festschrift to Honor Dr. Daniel Gilbert, A Half Century of Radical Ideas. Sponsored by the NIH ROS Interest Group and Washington Area Oxygen Club, July 2, 1998, Bethesda, Maryland.
79. Invited Speaker: "Development of Functional Electron Paramagnetic Resonance Imaging Using Free Radical Probes." Breast Cancer Think Tank Retreat, sponsored by the National Cancer Institute & the Division of Clinical Sciences. Westfields International Conference Center, Chantilly, Virginia, July, 1998.
80. Invited Speaker: "Principles of Chemoradiation: Theoretical and Practical Considerations." 2nd Bi-Annual Symposium on Concomitant Chemoradiotherapy, Nashville, TN, August, 1998.

81. Presentation: "Applications of EPR imaging with nitroxides to evaluate heterogeneities in tumor vs normal tissues." *In vivo* EPR and Related Studies, Dartmouth College, Hanover, NH, September 1998.
82. Invited Speaker: "Understanding Dose, Dose Rate, and Radiosensitizers." Cardiovascular Radiation Therapy for the Interventionalist. "Fundamentals of Radiation Biology for the Clinician." Radiation Vascular Therapy in Coronary and Peripheral Vascular Disease. Tenth Annual Symposium: Transcatheter Cardiovascular Therapeutics, October, 1998, Washington, D.C.
83. Invited Keynote Speaker: "Stable Nitroxide Free Radicals as Antioxidants, Radio-Protectors, and Imaging Agents." Radiation Research Laboratory, University of Iowa, 50th Anniversary Scientific Program, October, 1998, Iowa City, Iowa.
84. Invited Speaker: "Imaging of Free Radicals." ROS/RNS in Radiation-Induced Cell Injury and Disease. 5th Annual Meeting of the Oxygen Society, November, 1998, Washington, D.C.
85. Invited Speaker: "Functional Imaging Using Electron Paramagnetic Resonance." Conference of the Joint Working Group on Quantitative In Vivo Functional Imaging in Oncology, Sponsored by the U.S. Public Health Service's Office on Women's Health and the National Cancer Institute, Arlington, Virginia, January 1999.
86. Invited Speaker: "Protection Against Oxidative Stress by Nitroxides," Special Symposium, Society for Experimental Biology and Medicine and the Oxygen Club of Greater Washington, D.C., Bethesda, Maryland, February 1999.
87. Invited Symposium Speaker: "A Survey of In Vivo Antioxidant Effects of Nitroxides," Symposium: Antioxidants in Toxicology, American Chemical Society National Meeting, Anaheim, California, March, 1999.
88. Invited Speaker: "Oxidative Stress, Protection, and the Imaging of Free Radicals," Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, April, 1999.
89. Invited Speaker: "Oxidative Stress, Protection, and the Imaging of Free Radicals," Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, June, 1999.
90. Invited Speaker: "Stable Nitroxide Free Radicals as Antioxidants, Radiation Protectors, and Imaging Agents," In Vivo EPR Symposium, 41st Rocky Mountain Conference on Analytical Chemistry, Denver, Colorado, August, 1999.
91. Invited Speaker: "Hypoxia Modifiers," Symposium on Organ Preservation Therapies for Squamous Cancers of the Head and Neck, National Cancer Institute, National Institute for Deafness and Other Communication Disorders, and National Institute for Dental and Craniofacial Research, NIH, September, 1999, Bethesda, MD.

92. Invited Speaker: "Nitroxides as Protectors against Oxidative Stress," Lombardi Cancer Center's Tumor Biology Seminar Series, Georgetown University Medical Center, Washington, D.C., November, 1999.
93. Invited Speaker: "Nitroxides as Radiation Protectors," International Conference on Low-Level Radiation Injury and Medical Countermeasures, Armed Forces Radiobiology Research Institute, Bethesda, MD, November, 1999.
94. Invited Speaker: "Nitroxide Stable Free Radicals as Radiation Protectors." Eighth Annual Radiation Workshop at Round Top, M.D. Anderson Cancer Center, Round Top, Texas, April 2000.
95. Invited Speaker: Refresher Course: Molecular Biology-"Molecular Insights into the Cancer Cell." 42nd Annual Meeting of ASTRO. Boston, Massachusetts. October, 2000.
96. Invited Speaker: Education Session: "Electron Paramagnetic Resonance and Overhauser Enhanced MRI (EPR/OMRI)- In Vivo Imaging of Oxygen," 92nd Annual Meeting of the American Association for Cancer Research. New Orleans, LA. March 2001.
97. Invited Symposium Speaker: Biological Applications: "Nitroxide Free Radicals as Protectors Against Oxidative Stress." 43rd Rocky Mountain Conference on Analytical Chemistry. Denver, Colorado. July, 2001.
98. Invited Symposium Speaker: "Nitroxides as Protectors Against Oxidative Stress." 1st Annual Photobiology Working Group, Pennsylvania College of Optometry, Philadelphia, PA. November, 2001.
99. Invited Workshop Speaker: "Nitroxide Radioprotection." Interagency Workshop: Molecular and Cellular Biology of Moderate Dose Radiation and Potential Mechanisms of Radiation Protection. Sponsored jointly by NCI, DOD, DOE, and the Radiation Research Society. December 2001, Bethesda, Maryland.
100. Invited Speaker: "Novel Magnetic Resonance Imaging for Non-Invasive Assessment of Tissue Oxygen Concentration and Redox Status." Presidential Symposium: Metabolic Oxidative Stress and Cancer Therapy, Forty-ninth Annual Meeting of the Radiation Research Society, April 2002.
101. Invited Speaker: "Novel Magnetic Resonance Imaging for Non-Invasive Assessment of Tissue Oxygen Concentration and Redox Status." Tenth Annual Radiation Workshop at Round Top, (Tumor Microenvironment: Biology and Therapeutic Implications) M.D. Anderson Cancer Center, Round Top, Texas, April 2002.
102. Invited Chair: "EPR and MR Microscopy." Tenth Annual Meeting of the International Society for Magnetic Resonance in Medicine, Hawaii Convention Center, Honolulu, Hawaii, May 2002.
103. Invited Keynote Speaker: "Nitroxides as Antioxidants." Third International Conference on Oxygen/Nitrogen Radicals: Cell Injury and Disease. Sponsored by The Centers for

Disease Control and Prevention and The National Institute for Occupational Safety and Health. Morgantown, WV, June 2002.

104. Invited Symposium Speaker: "Stable Nitroxide Free Radicals, Oxidative Stress, and Functional Imaging." 7th International Symposium on Spin Trapping 2002," The Carolina Inn, Chapel Hill, North Carolina, July 2002.
105. Invited Speaker: "New EPR Imaging: Metabolism as an Imaging Target." Second NCI Young Investigators Workshop, Bethesda, MD, August 2002.
106. Invited Faculty Speaker: "Basic Concepts of Radiation Biology: Chemistry, Fractionation, and Sensitization." Radiation Biology Refresher Course for Radiation Oncology Residents. University of Maryland, Baltimore, Maryland, August 2002.
107. Invited Consultant: "Functional Imaging and Radiation Oncology." Centre for Biological Imaging and Adaptive Radiotherapy, Cross Cancer Institute, Edmonton, Alberta, Canada, August 2002.
108. Invited Speaker: "Imaging Using Electron Paramagnetic Resonance." Oxygen Homostasis/Hypoxia Workshop, NCI Cancer Therapy Evaluation Program/Developmental Therapeutics Program, Arlington, VA, February 2003.
109. Invited Speaker: "Functional Magnetic Resonance Imaging for Determination of Tissue Oxygen and Redox Status." Vascular Biology Faculty, Center for Cancer Research, NCI, Bethesda, MD, March 2003.
110. Invited Symposium Speaker: "Novel Magnetic Resonance Imaging for Tissue Oxygen Concentration in Cancer." Sixteenth Annual meeting of the Engineering and Urology Society, Chicago, IL, April 2003.
111. Invited Speaker: "What Radiobiologists do." Fifth Grade Career Fair, Liberty Elementary School, Libertytown, MD, May 2003.
112. Invited Speaker: "Novel Functional Imaging and Radiation Protection." Prostate Cancer Support Group, National Naval Medical Center, Bethesda, MD, May 2003.
113. Invited Symposium Speaker: "Novel Functional Imaging for Tissue Oxygen Concentration and Redox Status." Free Radicals: The Pros and Cons of Antioxidants, Divisions of Prevention and Cancer Treatment and Diagnosis, National Cancer Institute, National Center for Complementary and Alternative Medicine, Bethesda, MD, June 2003.
114. Invited Speaker: "Oxidative Stress and Applications of Functional Imaging." Pediatric Oncology Branch CME Seminar Series, National Cancer Institute, Bethesda, MD, October 2003.
115. Invited Symposium Speaker: "Nitroxide Antioxidants." 3rd Annual Photobiology Working Group, Pennsylvania College of Optometry, Philadelphia, PA. November 2003.

116. Invited Speaker: "Oxidative Stress, Radioprotection, and Applications of Novel Functional Imaging Technology" and "Radiation Biology Refresher for Radiation Oncology Residents." Eastern Virginia Medical School, CME Breast Oncology Lecture Series, Norfolk, VA, March 2004.
117. Invited Symposium Speaker: "Nitroxide –Mediated Radioprotection of Normal Tissues." Radiation Response Modifiers Symposium, 51st Annual Meeting of the Radiation Research Society, St. Louis, MO, April 2004.
118. Invited Symposium Speaker: "Imaging Hypoxia in Murine Squamous Cell Carcinoma using ⁶⁴Cu-ATSM." Biological Imaging Symposium, 51st Annual Meeting of the Radiation Research Society, St. Louis, MO, April 2004.
119. Invited Symposium Speaker: "Magnetic Resonance Imaging Approaches for Non-Invasive Assessment of Tissue Oxygen Concentration." Presidential Symposium, 51st Annual Meeting of the Radiation Research Society, St. Louis, MO, April 2004.
120. Invited Speaker: "What Research Scientists Do." Fifth Grade Career Fair, Liberty Elementary School, Libertytown, MD, May 2004.
121. Invited Speaker: "New Class of Antioxidants (Nitroxides) for Use as Radioprotectors." NIAID Biodefense Workshop: Animal Models for Radiation Injury, Protection, and Therapy, Bethesda, MD, May 2004.
122. Invited Lecturer: "Redox Biology and Cancer Treatment." NCI Redox Biology Course. Bethesda, MD, November 23, 2004.
123. Invited Speaker: "New Class of Antioxidants (Nitroxides) for use as Radioprotectants." Radiation Protection Workshop, Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office, December 13-14, 2004, Arlington, VA.
124. Invited Plenary Speaker: "Biologic Principles of Fractionation in Radiation Therapy." American College of Surgeons Oncology Group Semiannual Meeting, San Antonio, TX, January 14, 2005.
125. Invited Keynote Speaker: "Radiation Protection: Yesterday, Today, and Tomorrow." 18th Annual Meeting of the Oxygen Club of Greater Washington, Bethesda, MD, July 29, 2005.
126. Invited Plenary Lecturer: "Chasing Free Radicals: Therapeutic Applications of Nitroxides." 11th In Vivo EPR Spectroscopy and Imaging and 8th International EPR Spin Trapping Meeting, Columbus, OH, September 2005.
127. Invited Speaker: "Tissue Hypoxia Assessment using Electron Paramagnetic Resonance Imaging (EPRI)." 4th Annual NCI-RRP/ROSP Young Investigator Workshop, Bethesda, MD, September 2005.

128. Invited Speaker: "Chasing Free Radicals: Use of Nitroxide Antioxidants in Cancer Treatment and Prevention." Center for Cancer Research Grand Rounds, National Cancer Institute, Bethesda, MD, September 2005.
129. Invited Lecturer: "Chasing Free Radicals: Therapeutic Applications of Nitroxides." Department of Radiological Health Sciences, Colorado State University, Fort Collins, CO, October 2005.
130. Invited Speaker: "Novel Magnetic Resonance Approaches to Non-Invasively Measure Tissue Oxygen Concentration." NCI HIF Interest Group, Bethesda, MD, October 2005.
131. Invited Lecturer: "Redox Biology and Cancer Treatment." NCI Redox Biology Course. Bethesda, MD, November 15, 2005.

How Cancer Arises

An explosion of research is uncovering the long-hidden molecular underpinnings of cancer—and suggesting new therapies

by Robert A. Weinberg

How cancer develops is no longer a mystery. During the past two decades, investigators have made astonishing progress in identifying the deepest bases of the process—those at the molecular level. These discoveries are robust: they will survive the scrutiny of future generations of researchers, and they will form the foundation for revolutionary approaches to treatment. No one can predict exactly when therapies targeted to the molecular alterations in cancer cells will find wide use, given that the translation of new understanding into clinical practice is complicated, slow and expensive. But the effort is now under way.

In truth, the term “cancer” refers to more than 100 forms of the disease. Almost every tissue in the body can spawn malignancies; some even yield several types. What is more, each cancer has unique features. Still, the basic processes that produce these diverse tumors ap-

pear to be quite similar. For that reason, I will refer in this article to “cancer” in generic terms, drawing on one or another type to illustrate the rules that seem to apply universally.

The 30 trillion cells of the normal, healthy body live in a complex, interdependent condominium, regulating one another's proliferation. Indeed, normal cells reproduce only when instructed to do so by other cells in their vicinity. Such unceasing collaboration ensures that each tissue maintains a size and architecture appropriate to the body's needs.

Cancer cells, in stark contrast, violate this scheme; they become deaf to the usual controls on proliferation and follow their own internal agenda for reproduction. They also possess an even more insidious property—the ability to migrate from the site where they began, invading nearby tissues and forming masses at distant sites in the body. Tumors composed of such malignant cells

become more and more aggressive over time, and they become lethal when they disrupt the tissues and organs needed for the survival of the organism as a whole.

This much is not new. But over the past 20 years, scientists have uncovered a set of basic principles that govern the development of cancer. We now know that the cells in a tumor descend from a common ancestral cell that at one point—usually decades before a tumor becomes palpable—initiated a program of inappropriate reproduction. Further, the malignant transformation of a cell comes about through the accumulation of mutations in specific classes of the genes within it. These genes provide the key to understanding the processes at the root of human cancer.

Genes are carried in the DNA molecules of the chromosomes in the cell nucleus. A gene specifies a sequence of amino acids that must be linked together to make a particular protein; the protein then carries out the work of the gene. When a gene is switched on, the cell responds by synthesizing the encoded protein. Mutations in a gene can perturb a cell by changing the amounts or the activities of the protein product.

Two gene classes, which together constitute only a small proportion of the full genetic set, play major roles in triggering cancer. In their normal configuration, they choreograph the life cycle of the cell—the intricate sequence of events by which a cell enlarges and divides. Proto-oncogenes encourage such growth, whereas tumor suppressor genes inhibit it. Collectively these two gene classes ac-

Tumor Development Occurs in Stages

The creation of a malignant tumor in epithelial tissue is depicted schematically below. Epithelial cancers are the most common malignancies and are called carcinomas. The mass seen here emerges as a result of mutations in four genes, but the number of genes involved in real tumors can vary.

GENETICALLY ALTERED CELL

HYPERPLASIA

DYSPLASIA

1 Tumor development begins when some cell (orange) within a normal population (beige) sustains a genetic mutation that increases its propensity to proliferate when it would normally rest.

2 The altered cell and its descendants continue to look normal, but they reproduce too much—a condition termed hyperplasia. After years, one in a million of these cells (pink) suffers another mutation that further loosens controls on cell growth.

3 In addition to proliferating excessively, the offspring of this cell appear abnormal in shape and in orientation; the tissue is now said to exhibit dysplasia. Once again, after a time, a rare mutation that alters cell behavior occurs (purple).

DANA BURNS-PIZER

count for much of the uncontrolled cell proliferation seen in human cancers.

When mutated, proto-oncogenes can become carcinogenic oncogenes that drive excessive multiplication. The mutations may cause the proto-oncogene to yield too much of its encoded growth-stimulatory protein or an overly active form of it. Tumor suppressor genes, in contrast, contribute to cancer when they are inactivated by mutations. The resulting loss of functional suppressor proteins deprives the cell of crucial brakes that prevent inappropriate growth.

For a cancerous tumor to develop, mutations must occur in half a dozen or more of the founding cell's growth-controlling genes. Altered forms of yet other classes of genes may also participate in the creation of a malignancy, by specifically enabling a proliferating cell to become invasive or capable of spreading (metastasizing) throughout the body.

Signaling Systems Go Awry

Vital clues to how mutated proto-oncogenes and tumor suppressor genes contribute to cancer came from studying the roles played within the cell by the normal counterparts of these genes. After almost two decades of research, we now view the normal genetic functions with unprecedented clarity and detail.

Many proto-oncogenes code for proteins in molecular "bucket brigades" that relay growth-stimulating signals from outside the cell deep into its interior. The growth of a cell becomes deregulated

when a mutation in one of its proto-oncogenes energizes a critical growth-stimulatory pathway, keeping it continuously active when it should be silent.


These pathways within a cell receive and process growth-stimulatory signals transmitted by other cells in a tissue. Such cell-to-cell signaling usually begins when one cell secretes growth factors. After release, these proteins move through the spaces between cells and bind to specific receptors—antennalike molecules—on the surface of other cells nearby. Receptors span the outer membrane of the target cells, so that one end protrudes into the extracellular space, and the other end projects into the cell's interior, its cytoplasm. When a growth-stimulatory factor attaches to a receptor, the receptor conveys a proliferative signal to proteins in the cytoplasm. These downstream proteins then emit stimulatory signals to a succession of other proteins, in a chain that ends in the heart of the cell, its nucleus. Within the nucleus, proteins known as transcription factors respond by activating a cohort of genes that help to usher the cell through its growth cycle.

Some oncogenes force cells to overproduce growth factors. Sarcomas and gliomas (cancers, respectively, of connective tissues and nonneuronal brain cells) release excessive amounts of platelet-derived growth factor. A number of

other cancer types secrete too much transforming growth factor alpha. These factors act, as usual, on nearby cells, but, more important, they may also turn back and drive proliferation of the same cells that just produced them.


Researchers have also identified oncogenic versions of receptor genes. The aberrant receptors specified by these oncogenes release a flood of proliferative signals into the cell cytoplasm even when no growth factors are present to urge the cell to replicate. For instance, breast cancer cells often display Erb-B2 receptor molecules that behave in this way.

Still other oncogenes in human tumors perturb parts of the signal cascade found in the cytoplasm. The best understood example comes from the *ras* family of oncogenes. The proteins encoded by normal *ras* genes transmit stimulatory signals from growth factor receptors to other proteins farther down the line. The proteins encoded by mutant *ras* genes, however, fire continuously, even when growth factor receptors are not prompting them. Hyperactive Ras proteins are found in about a quarter of all human tumors, including carcinomas of the colon, pancreas and lung. (Carcinomas are by far the most common forms of cancer; they originate in epithelial cells, which line the body cavities



4 The affected cells become still more abnormal in growth and appearance. If the tumor has not yet broken through any boundaries between tissues, it is called in situ cancer. This tumor may remain contained indefinitely; however, some cells may eventually acquire additional mutations (blue).

5 If the genetic changes allow the tumor to begin invading underlying tissue and to shed cells into the blood or lymph, the mass is considered to have become malignant. The renegade cells are likely to establish new tumors (metastases) throughout the body; these may become lethal by disrupting a vital organ.



SIGNALING PATHWAYS in normal cells convey growth-controlling messages from the outer surface deep into the nucleus. There a molecular apparatus known as the cell cycle clock collects the messages and decides whether the cell should divide. Cancer cells often proliferate excessively because genetic mutations cause stimulatory pathways (*green*) to issue too many "go" signals or because inhibitory pathways (*red*) can no longer

convey "stop" signals. A stimulatory pathway will become hyperactive if a mutation causes any component, such as a growth factor receptor (*box at left*), to issue stimulatory messages autonomously, without waiting for commands from upstream. Conversely, inhibitory pathways will shut down when some constituent, such as a cytoplasmic relay (*box at right*), is eliminated and thus breaks the signaling chain.

and form the outer layer of the skin.)

Yet other oncogenes, such as those in the *myc* family, alter the activity of transcription factors in the nucleus. Cells normally manufacture Myc transcription factors only after they have been stimulated by growth factors impinging on the cell surface. Once made, Myc proteins activate genes that force cell growth forward. But in many types of cancer, especially malignancies of the blood-forming tissues, Myc levels are kept constantly high even in the absence of growth factors.

Discovery of trunk lines that carry proliferative messages from the cell surface to its nucleus has been more than intellectually satisfying. Because these pathways energize the multiplication of malignant cells, they constitute attractive targets for scientists intent on developing new types of anticancer thera-

peutics. In an exciting turn of events, as many as half a dozen pharmaceutical companies are working on drugs designed to shut down aberrantly firing growth factor receptors. At least three other companies are attempting to develop compounds that block the synthesis of aberrant Ras proteins. Both groups of agents halt excessive signaling in cultured cancer cells, but their utility in blocking the growth of tumors in animals and humans remains to be demonstrated.

Tumor Suppressors Stop Working

To become malignant, cells must do more than overstimulate their growth-promoting machinery. They must also devise ways to evade or ignore braking signals issued by their normal neighbors in the tissue. Inhibitory messages received by a normal cell flow

to the nucleus much as stimulatory signals do—via molecular bucket brigades. In cancer cells, these inhibitory brigades may be disrupted, thereby enabling the cell to ignore normally potent inhibitory signals at the surface. Critical components of these brigades, which are specified by tumor suppressor genes, are absent or inactive in many types of cancer cells.

A secreted substance called transforming growth factor beta (TGF- β) can stop the growth of various kinds of normal cells. Some colon cancer cells become oblivious to TGF- β by inactivating a gene that encodes a surface receptor for this substance. Some pancreatic cancers inactivate the *DPC4* gene, whose protein product may operate downstream of the growth factor receptor. And a variety of cancers discard the *p15* gene, which codes for a protein that, in re-

sponse to signals from TGF- β , normally shuts down the machinery that guides the cell through its growth cycle.

Tumor suppressor proteins can also restrain cell proliferation in other ways. Some, for example, block the flow of signals through growth-stimulatory circuits. One such suppressor is the product of the *NF-1* gene. This cytoplasmic molecule ambushes the Ras protein before it can emit its growth-promoting directives. Cells lacking *NF-1*, then, are missing an important counterbalance to Ras and to unchecked proliferation.

Various studies have shown that the introduction of a tumor suppressor gene into cancer cells that lack it can restore a degree of normalcy to the cells. This response suggests a tantalizing way of combating cancer—by providing cancer cells with intact versions of tumor suppressor genes they lost during tumor development. Although the concept is attractive, this strategy is held back by the technical difficulties still encumbering gene therapy for many diseases. Current procedures fail to deliver genes to a large proportion of the cells in a tumor. Until this logistical obstacle is surmounted, the use of gene therapy to cure cancer will remain a highly appealing but unfulfilled idea.

The Clock Is Struck

Over the past five years, impressive evidence has uncovered the destination of stimulatory and inhibitory pathways in the cell. They converge on a molecular apparatus in the cell nucleus that is often referred to as the cell cycle clock. The clock is the executive decision maker of the cell, and it apparently runs amok in virtually all types of human cancer. In the normal cell, the clock integrates the mixture of growth-regulating signals received by the cell and decides whether the cell should pass through its life cycle. If the answer is positive, the clock leads the process.

The cell cycle is composed of four stages. In the G_1 (gap 1) phase, the cell increases in size and prepares to copy its DNA. This copying occurs in the next stage, termed S (for synthesis), and enables the cell to duplicate precisely its complement of chromosomes. After the chromosomes are replicated, a second gap period, termed G_2 , follows during which the cell prepares itself for M (mitosis)—the time when the enlarged par-

Some Genes Involved in Human Cancers

Genes known as proto-oncogenes code for proteins that stimulate cell division; mutated forms, called oncogenes, can cause the stimulatory proteins to be overactive, with the result that cells proliferate excessively. Tumor suppressor genes code for proteins that inhibit cell division. Mutations can cause the proteins to be inactivated and may thus deprive cells of needed restraints on proliferation. Investigators are still trying to decipher the specific functions of many tumor suppressor genes.

ONCOGENES

Genes for growth factors or their receptors

<i>PDGF</i>	Codes for platelet-derived growth factor. Involved in glioma (a brain cancer)
<i>erb-B</i>	Codes for the receptor for epidermal growth factor. Involved in glioblastoma (a brain cancer) and breast cancer
<i>erb-B2</i>	Also called <i>HER-2</i> or <i>neu</i> . Codes for a growth factor receptor. Involved in breast, salivary gland and ovarian cancers
<i>RET</i>	Codes for a growth factor receptor. Involved in thyroid cancer

Genes for cytoplasmic relays in stimulatory signaling pathways

<i>Ki-ras</i>	Involved in lung, ovarian, colon and pancreatic cancers
<i>N-ras</i>	Involved in leukemias

Genes for transcription factors that activate growth-promoting genes

<i>c-myc</i>	Involved in leukemias and breast, stomach and lung cancers
<i>N-myc</i>	Involved in neuroblastoma (a nerve cell cancer) and glioblastoma
<i>L-myc</i>	Involved in lung cancer

Genes for other kinds of molecules

<i>Bcl-2</i>	Codes for a protein that normally blocks cell suicide. Involved in follicular B cell lymphoma
<i>Bcl-1</i>	Also called <i>PRAD1</i> . Codes for cyclin D1, a stimulatory component of the cell cycle clock. Involved in breast, head and neck cancers
<i>MDM2</i>	Codes for an antagonist of the p53 tumor suppressor protein. Involved in sarcomas (connective tissue cancers) and other cancers

TUMOR SUPPRESSOR GENES

Genes for proteins in the cytoplasm

<i>APC</i>	Involved in colon and stomach cancers
<i>DPC4</i>	Codes for a relay molecule in a signaling pathway that inhibits cell division. Involved in pancreatic cancer
<i>NF-1</i>	Codes for a protein that inhibits a stimulatory (Ras) protein. Involved in neurofibroma and pheochromocytoma (cancers of the peripheral nervous system) and myeloid leukemia
<i>NF-2</i>	Involved in meningioma and ependymoma (brain cancers) and schwannoma (affecting the wrapping around peripheral nerves)

Genes for proteins in the nucleus

<i>MTS1</i>	Codes for the p16 protein, a braking component of the cell cycle clock. Involved in a wide range of cancers
<i>RB</i>	Codes for the pRB protein, a master brake of the cell cycle. Involved in retinoblastoma and bone, bladder, small cell lung and breast cancer
<i>p53</i>	Codes for the p53 protein, which can halt cell division and induce abnormal cells to kill themselves. Involved in a wide range of cancers
<i>WT1</i>	Involved in Wilms' tumor of the kidney

Genes for proteins whose cellular location is not yet clear

<i>BRCA1</i>	Involved in breast and ovarian cancers
<i>BRCA2</i>	Involved in breast cancer
<i>VHL</i>	Involved in renal cell cancer

ent cell finally divides in half to produce its two daughters, each of which is endowed with a complete set of chromosomes. The new daughter cells immediately enter G_1 and may go through the full cycle again. Alternatively, they may stop cycling temporarily or permanently.

The cell cycle clock programs this elaborate succession of events by means

of a variety of molecules. Its two essential components, cyclins and cyclin-dependent kinases (CDKs), associate with one another and initiate entrance into the various stages of the cell cycle. In G_1 , for instance, D-type cyclins bind to CDKs 4 or 6, and the resulting complexes act on a powerful growth-inhibitory molecule—the protein known as pRB.

This action releases the braking effect of pRB and enables the cell to progress into late G_1 and thence into S (DNA synthesis) phase [see *b* in box below].

Various inhibitory proteins can restrain forward movement through the cycle. Among them are p15 (mentioned earlier) and p16, both of which block the activity of the CDK partners of cy-

The Cell Cycle Clock and Cancer


Most, perhaps all, human cancers grow inappropriately not only because signaling pathways in cells are perturbed but also because the so-called cell cycle clock becomes deranged. The clock—composed of an assembly of interacting proteins in the nucleus—normally integrates messages from the stimulatory and inhibitory pathways and, if the stimulatory messages win out, programs a cell's advance through its cycle of growth and division. Progression through the four stages of the cell cycle (a) is

driven to a large extent by rising levels of proteins called cyclins: first the D type, followed by E, A and then B.

A crucial step in the cycle occurs late in G_1 at the restriction point (R), when the cell decides whether to commit itself to completing the cycle. For the cell to pass through R and enter S, a molecular "switch" must be flipped from "off" to "on." The switch works as follows (b): As levels of cyclin D and, later, cyclin E rise, these proteins combine with and activate enzymes called cyclin-dependent kinases (1). The kinases (acting as part of cyclin-kinase complexes) grab phosphate groups (2) from molecules of


a

STAGES OF THE CELL CYCLE




b

A MOLECULAR "SWITCH"



c

THE CELL CYCLE CLOCK IN ACTION




Breast cancer cells often produce excesses of cyclin D and cyclin E. In many cases of melanoma, skin cells have lost the gene encoding the braking protein p16. Half of all types of human tumors lack a functional p53 protein. And in cervical cancers triggered by infection of cells with a human papillomavirus, both the pRB and p53 proteins are fre-

ATP (adenosine triphosphate) and transfer them to a protein called pRB, the master brake of the cell cycle clock. When pRB lacks phosphates, it actively blocks cycling (and keeps the switch in the “off” position) by sequestering other proteins termed transcription factors. But after the cyclin-kinase complexes add enough phosphates to pRB, the brake stops working (3; *bottom*);

In figure c below, the switch is placed in the larger context of the many molecular interactions that regulate the cell cycle. Flipping of the switch to "on" can be seen above the R point. Overactivity of the stimulatory proteins cyclin D, cyclin E and CDK4 have been implicated in certain human cancers. Inactivation of various inhibitory proteins has also been documented. The affected proteins include p53 (lost or ineffective in more than half of all tumor types), pRB, p16 and p15. The net effect of any of these changes is deregulation of the clock and, in turn, excessive proliferation of the cell.

—R.A.W.




I have so far discussed two ways that our tissues normally hold down cell proliferation and avoid cancer. They prevent excess multiplication by depriving a cell of growth-stimulatory factors or, conversely, by showering it with antiproliferative factors. Still, as we have seen, cells on their way to becoming cancerous often circumvent these controls: they stimulate themselves and turn a deaf ear

whole: the potential dangers posed to the organism by carcinogenic mutations are far greater than the small price paid in the loss of a single cell. The tumors that emerge in our tissues, then, would seem to arise from the rare, genetically disturbed cell that somehow succeeds in evading the apoptotic program hardwired into its control circuitry.

Developing cancer cells devise several

evade apoptosis will be far less responsive to treatment. By the same token, it suggests that therapies able to restore a cell's capacity for suicide could combat cancer by improving the effectiveness of existing radiation and chemotherapeutic treatment strategies.

A second defense against runaway proliferation, quite distinct from the apoptotic program, is built into our cells



HUMAN CHROMOSOMES from a normal dividing cell (*top*) occur as identical pairs; those numbered 8 to 18 are shown. Chromosomes from a cervical cancer cell, in contrast, display many abnormalities (*bottom*). Chromosome 8, for instance, exhibits three disturbances: gain of copy number; deletion of genetic material from individual copies; and breakage followed by joining of segments that do not belong together (*far right in 8*). Copy loss, as in chromosome 13, is also common. These various changes can favor tumor progression if they activate an oncogene, increase the copies of an oncogene or eliminate a tumor suppressor gene. The images were generated by spectral karyotyping, a new method for analyzing chromosomes.

to inhibitory signals. Prepared for such eventualities, the human body equips cells with certain backup systems that guard against runaway division. But additional mutations in the cell's genetic repertoire can overcome even these defenses and contribute to cancer.

Fail-Safe Systems Fail

One such backup system, present in each human cell, provokes the cell to commit suicide (undergo "apoptosis") if some of its essential components are damaged or if its control systems are deregulated. For example, injury to chromosomal DNA can trigger apoptosis. Further, recent work from a number of laboratories indicates that creation of an oncogene or the disabling of a tumor suppressor gene within a cell can also induce this response. Destruction of a damaged cell is bad for the cell itself but makes sense for the body as a

means of evading apoptosis. The p53 protein, among its many functions, helps to trigger cell suicide; its inactivation by many tumor cells reduces the likelihood that genetically troubled cells will be eliminated. Cancer cells may also make excessive amounts of the protein Bcl-2, which wards off apoptosis efficiently.

Recently scientists have realized that this ability to escape apoptosis may endanger patients not only by contributing to the expansion of a tumor but also by making the resulting tumors resistant to therapy. For years, it was assumed that radiation therapy and many chemotherapeutic drugs killed malignant cells directly, by wreaking widespread havoc in their DNA. We now know that the treatments often harm DNA to a relatively minor extent. Nevertheless, the affected cells perceive that the inflicted damage cannot be repaired easily, and they actively kill themselves. This discovery implies that cancer cells able to


as well. This mechanism counts and limits the total number of times cells can reproduce themselves.

Cells Become Immortal

Much of what is known about this safeguard has been learned from studies of cells cultured in a petri dish. When cells are taken from a mouse or human embryo and grown in culture, the population doubles every day or so. But after a predictable number of doublings—50 to 60 in human cells—growth stops, at which point the cells are said to be senescent. That, at least, is what happens when cells have intact *RB* and *p53* genes. Cells that sustain inactivating mutations in either of these genes continue to divide after their normal counterparts enter senescence. Eventually, though, the survivors reach a second stage, termed crisis, in which they die in large numbers. An occasional cell in this dying population, however, will escape crisis and become immortal: it and its descendants will multiply indefinitely.

These events imply the existence of a mechanism that counts the number of doublings through which a cell population has passed. During the past several years, scientists have discovered the molecular device that does this counting. DNA segments at the ends of chromo-

somes, known as telomeres, tally the number of replicative generations through which cell populations pass and, at appropriate times, initiate senescence and crisis. In so doing, they circumscribe the ability of cell populations to expand indefinitely [see "Telomeres, Telomerase and Cancer," by Carol W. Greider and Elizabeth H. Blackburn; SCIENTIFIC AMERICAN, February].



Like the plastic tips on shoelaces, the telomere caps protect chromosomal ends from damage. In most human cells, telomeres shorten a bit every time chromosomes are replicated during the S phase of the cell cycle. Once the telomeres shrink below some threshold length, they sound an alarm that instructs cells to enter senescence. If cells bypass senescence, further shrinkage of the telomere will eventually trigger crisis: extreme shortening of the telomeres will cause the chromosomes in a cell to fuse with one another or to break apart, creating genetic chaos that is fatal to the cell.

If the telomere-based counting system operated properly in cancerous cells, their excessive proliferation would be aborted long before tumors became very large. Dangerous expansion would be stemmed by the senescence program or, if the cell evaded that blockade, by disruption of the chromosomal array at crisis. But this last defense is breached during the development of most cancer cells, overcome by activation of a gene that codes for the enzyme telomerase.

This enzyme, virtually absent from most healthy cell types but present in almost all tumor cells, systematically replaces telomeric segments that are usually trimmed away during each cell cycle. In so doing, it maintains the integrity of the telomeres and thereby enables

cells to replicate endlessly. The resulting cell immortality can be troublesome in a couple of ways. Obviously, it allows tumors to grow large. It also gives precancerous or already cancerous cells time to accumulate additional mutations that will increase their ability to replicate, invade and ultimately metastasize.

From the point of view of a cancer cell, production of a single enzyme is a clever way to topple the mortality barrier. Yet dependence on one enzyme may represent an Achilles' heel as well. If telomerase could be blocked in cancer cells, their telomeres would once again shrink whenever they divided, pushing these cells into crisis and death. For that reason, a number of pharmaceutical firms are attempting to develop drugs that target telomerase.

Why Some Cancers Appear Early

It normally takes decades for an incipient tumor to collect all the mutations required for its malignant growth. In some individuals, however, the time for tumor development is clearly compressed; they contract certain types of cancer decades before the typical age of onset of these cancers. How can tumor formation be accelerated?

In many cases, this early onset is explained by the inheritance from one or the other parent of a mutant cancer-causing gene. As a fertilized egg begins to divide and replicate, the set of genes provided by the sperm and egg is copied and distributed to all the body's cells. Now a typically rare event—a mutation in a critical growth-controlling gene—becomes ubiquitous, because the mutation is implanted in all the body's cells, not merely in some randomly stricken cell. In other words, the process of tumor formation leapfrogs over one of its early, slowly occurring steps, accelerating the process as a whole. As a consequence, tumor development, which usually requires three or four decades to reach completion, may culminate in one or two. Because such mutant genes can pass from generation to generation, many members of a family may be at risk for the early development of cancer.

An inherited form of colon cancer provides a dramatic example. Most cases of colon cancer occur sporadically, the results of random genetic events occurring during a person's lifetime. In certain families, however, many individuals are af-

flicted with early-onset colonic tumors, preordained by an inherited gene. In the sporadic cases, a rare mutation silences a tumor suppressor gene called APC in an intestinal epithelial cell. The resulting proliferation of the mutant cell yields a benign polyp that may eventually progress to a malignant carcinoma. But defective forms of APC may pass from parents to children in certain families. Members of these families develop hundreds, even thousands of colonic polyps during the first decades of life, some of which are likely to become transformed into carcinomas.

The list of familial cancer syndromes that are now traceable directly to inheritance of mutant tumor suppressor genes is growing. For instance, inherited defective versions of the gene for *pRB* often lead to development of an eye cancer—retinoblastoma—in children; later in life the mutations account for a greatly increased risk of osteosarcomas (bone cancers). Mutant inherited versions of the *p53* tumor suppressor gene yield tumors at multiple sites, a condition known as the Li-Fraumeni syndrome (named in part for Frederick Li, co-author of "What Causes Cancer?," page 80). And the recently isolated *BRCA1* and *BRCA2* genes seem to account for the bulk of familial breast cancers, encompassing as many as 20 percent of all premenopausal breast cancers in this country and a substantial proportion of familial ovarian cancers as well.

Early onset of tumors is sometimes explained by inheritance of mutations in another class of genes as well. As I implied earlier, most people avoid cancer until late in life or indefinitely because they enter the world with pristine genes. During the course of a lifetime, however, our genes are attacked by carcinogens imported into our bodies from the environment and also by chemicals produced in our own cells. And genetic errors may be introduced when the enzymes that replicate DNA during cell cycling make copying mistakes. For the most part, such errors are rapidly corrected by a repair system that operates in every cell. Should the repair system slip up and fail to erase an error, the damage will become a permanent mutation in one of the cell's genes and in that same gene in all descendant cells.

The system's high repair efficiency is one reason many decades can pass before all the mutations needed for a ma-

lignancy to develop will, by chance, come together within a single cell. Certain inherited defects, though, can accelerate tumor development through a particularly insidious means: they impair the operation of proteins that repair damaged DNA. As a result, mutations that would normally accumulate slowly will appear with alarming frequency throughout the DNA of cells. Among the affected genes are inevitably those controlling cell proliferation.

Such is the case in another inherited colon cancer, hereditary nonpolyposis colon cancer. Afflicted individuals make defective versions of a protein responsible for repairing the copying mistakes made by the DNA replication apparatus. Because of this impairment, colonic cells cannot fix DNA damage efficiently; they therefore collect mutations rapidly, accelerating cancer development by two decades or more. People affected by another familial cancer syndrome, xeroderma pigmentosum, have inherited a defective copy of a gene that directs the repair of DNA damaged by ultraviolet rays. These patients are prone to several types of sunlight-induced skin cancer.

Similarly, cells of people born with a defective *ATM* gene have difficulty recognizing the presence of certain lesions in the DNA and mobilizing the appropriate repair response. These people are susceptible to neurological degeneration, blood vessel malformation and a variety of tumors. Some researchers have proposed that as many as 10 percent of inherited breast cancers may arise in patients with a defective copy of this gene.

Over the next decade, the list of cancer susceptibility genes will grow dramatically, one of the fruits of the Human Genome Project (which seeks to identify every gene in the human cell). Together with the increasingly powerful tools of DNA analysis, knowledge of these genes

will enable us to predict which members of cancer-prone families are at high risk and which have, through good fortune, inherited intact copies of these genes.

Beyond Proliferation

Although we have learned an enormous amount about the genetic basis of runaway cell proliferation, we still know rather little about the mutant genes that contribute to later stages of tumor development, specifically those that allow tumor cells to attract blood vessels for nourishment, to invade nearby tissues and to metastasize. But research in these areas is moving rapidly. (Judah Folkman describes the ingenuity of tumor cells in generating their own blood supply in "Fighting Cancer by Attacking Its Blood Supply," on page 150. Erkki Ruoslahti takes up metastasis in "How Cancer Spreads" on page 72.)

We are within striking distance of writing the detailed life histories of many human tumors from start to life-threatening finish. These biographies will be written in the language of genes and molecules. Within a decade, we will know with extraordinary precision the succession of events that constitute the complex evolution of normal cells into highly malignant, invasive derivatives.

By then, we may come to understand why certain localized masses never progress beyond their benign, noninvasive form to confront us with aggressive malignancy. Such benign growths can be found in almost every organ of the body. Perhaps we will also discern why certain mutant genes contribute to the formation of some types of cancer but not others. For example, mutant versions of the *RB* tumor suppressor gene appear often in retinoblastoma, bladder carcinoma and small cell lung carcinoma but are seen only occasionally in breast and colon car-

cinomas. Very likely, many of the solutions to these mysteries will flow from research in developmental biology (embryology). After all, the genes that govern embryonic development are, much later, the sources of our malignancies.

By any measure, the amount of information gathered over the past two decades about the origins of cancer is without parallel in the history of biomedical research. Some of this knowledge has already been put to good use, to build molecular tools for detecting and determining the aggressiveness of certain types of cancer, as David Sidransky discusses in "Advances in Cancer Detection," on page 104. Still, despite so much insight into cause, new curative therapies have so far remained elusive. One reason is that tumor cells differ only minimally from healthy ones; a minute fraction of the tens of thousands of genes in a cell suffers damage during malignant transformation. Thus, normal friend and malignant foe are woven of very similar cloth, and any fire directed against the enemy may do as much damage to normal tissue as to the intended target.

Yet the course of the battle is changing. The differences between normal and cancer cells may be subtle, but they are real. And the unique characteristics of tumors provide excellent targets for intervention by newly developed drugs [see the section "Therapies of the Future," beginning on page 135]. The development of targeted anticancer therapeutics is still in its infancy. This enterprise will soon move from hit-or-miss, serendipitous discovery to rational design and accurate targeting. I suspect that the first decade of the new century will reward us with cancer therapies that earlier generations could not have dreamed possible. Then this nation's long investment in basic cancer research will begin to pay off handsomely. □

The Author

ROBERT A. WEINBERG is Member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology, where he earned his doctoral degree in biology in 1969. His laboratory was instrumental in isolating the first human oncogene and the first human tumor suppressor gene. Weinberg, a member of the National Academy of Sciences, has won many awards for his contributions to the understanding of cancer genetics, most recently the G.H.A. Clowes Memorial Award of the American Association for Cancer Research. This is his fourth article for *Scientific American*.

Further Reading

CANCER: SCIENCE AND SOCIETY. J. Cairns. W. H. Freeman, 1978.
GENES AND THE BIOLOGY OF CANCER. H. Varmus and R. A. Weinberg. Scientific American Library (distributed by W. H. Freeman), 1993.
THE MULTISTEP NATURE OF CANCER. B. Vogelstein and K. W. Kinzler in *Trends in Genetics*, Vol. 9, No. 4, pages 138-141; April 1993.
CANCER: THE RISE OF THE GENETIC PARADIGM. J. M. Bishop in *Genes and Development*, Vol. 9, No. 11, pages 1309-1315; June 1, 1995.
ONCOGENES. Second edition. G. M. Cooper. Jones and Bartlett Publishers, Boston, 1995.

The multistep nature of cancer

BERT VOGELSTEIN AND KENNETH W. KINZLER

One of the most important developments in genetics over the past decade has been the proof that cancer is, in essence, a genetic disease. However, there are two key differences between cancer and most other genetic diseases. First, cancer is, for the most part, caused by somatic mutations, whereas all other genetic diseases of mammals (excluding those involving mitochondrial genes) are caused solely by germ-line mutations. Second, each individual cancer arises not from a single mutation, but from the accumulation of several mutations. This 'multi-hit' concept is central to understanding neoplasia, but only in the past decade has it become possible to provide support for this concept at the molecular level. Here, we review some of the many studies that have substantiated this view.

Epidemiology

If one plots the incidence of most common human cancers against age, a striking relationship is observed: the incidence rate increases dramatically (10^3 – 10^7 times) with age (Fig. 1). Although there are many possible explanations for the exponential relationship, the most attractive is that three to seven 'hits' are required for a cancer to form¹. These 'hits' could represent insults to separate cells, but because each cancer appears to arise from a single cellular progenitor (clonal growth) it is more likely that they represent sequential mutations of growth-regulatory genes in a single cell and its progeny.

According to this idea, tumors grow by a process of clonal evolution driven by mutation². The first mutation would result in limited expansion of the progeny of a single cell. One of these cells would later acquire a second mutation, perhaps allowing growth of a small benign tumor. One cell within this benign tumor would then undergo a third mutation, overgrow its sister cells, and form a more advanced tumor composed of progeny cells with three mutations. Eventually the cell will accumulate a sufficient number of hits to make it malignant, enabling it to invade

surrounding tissues and metastasize to other organs (the latter properties alone distinguish malignant tumors, cancers, from benign tumors). In this sequential multi-hit model of carcinogenesis, the fact that most cancers occur in older people is explained by the decades required for an individual to accumulate the number of mutations necessary to cause malignancy.

Other epidemiological and clinical observations were critical in formulating the multi-hit hypothesis. For example, patients exposed to radiation often develop cancer, but the cancers do not form immediately. In the case of patients who underwent X-ray therapy for tuberculosis, breast cancers develop an average of 15 years after the initial exposure³. Why the long time lag? One explanation is that the radiation induced a mutation in a cell, but additional mutations in the progeny of this cell were required for a cancer to form. Again, because of the low incidence of additional mutations after radiation therapy had ended, long periods were required for the cancer to appear.

Morphological observations are also in accord with the multi-hit hypothesis. In the colon, the gradual evolution of tumors is well documented. Small benign tumors (adenomas) are the first manifestations of neoplasia in colorectal epithelium. These tumors are only a few millimeters in diameter and are almost normal in their intra- and intercellular organization. With time, these tumors grow and their cells become more disorganized. Eventually, the tumor evolves into a cancer (carcinoma), presumably because one of the cells in the adenoma has acquired a sufficient number of mutations to drive the processes of invasion and metastasis. These morphological observations on colonic tumors have now been supplemented by documentation of the mutations that are associated with initiation and progression⁴. For example, it has been shown that malignant cells within a single tumor have the same set of mutations found in benign portions of the tumor, but with the addition of at least one further mutation that is absent in the benign precursor cells. A similar evolution of morphology has been observed in cervical carcinomas. The cervical smear test is used to detect neoplastic cells shed from the cervix at a stage before full-blown malignancy. Surgery at this stage can be life-saving, whereas once the tumor has acquired the ability to metastasize through sequential mutation, the resultant cancers are often incurable.

The examples given above suggest that multiple mutations occurring over decades drive the neoplastic process. Exceptions to this general scenario provide




FIG 1

Cancer incidence versus age. The log of the incidence rate and the log of age have a linear relationship, with the incidence increasing according to a power of age. Modified from Ref. 1.

REVIEWS

important lessons. Tumors that occur in children obviously do not take decades to develop. The timing of tumorigenesis in such cases stimulated Knudson to propose his now well-accepted model for neoplastic development⁵. The model invokes two important principles. First, in childhood tumors of the eye and kidney, only two mutations are rate limiting for cancer formation. Second, either the two mutations can both develop somatically, or one can be inherited and the other somatic. In the latter case, every eye or kidney cell of the individual has a 'head start' on the neoplastic process, and such individuals have a high risk of developing these specific cancers. One important finding from these pediatric studies is that the number of hits required is likely to vary in different cell types. Similarly, it may vary in different species. For example, rodent cells are generally easier to transform than human cells, and this may be because fewer hits are required.

Transformation *in vitro*

The morphological and epidemiological observations noted above only indirectly support the multi-hit scenario. More direct evidence is provided by gene transfer experiments. An oncogene can be operationally defined as a gene whose activity leads to enhanced cell growth. If an oncogene is transferred to cultured primary rodent fibroblasts under standard conditions, no changes in growth are observed. However, if two oncogenes are transferred simultaneously, the recipient cells grow abnormally well *in vitro*, forming foci of piled-up cells. These foci are tumorigenic when implanted into mice⁶. Moreover, not all combinations of oncogenes will transform cells, so that oncogenes can be classified by their ability to complement one another in transformation assays. This suggests that the cell has evolved several growth control circuits, and more than one circuit must be damaged before abnormal growth ensues. Thus, an oncogene that disrupts one circuit can be complemented in transformation assays by a gene that disrupts a second circuit, but if both oncogenes act through the same circuit the cell maintains sufficient control to prevent neoplastic transformation.

An interesting new example of this synergy involves *c-myc* and *bcl-2*. Overexpression of *c-myc* is often associated with neoplastic growth. However, *c-myc* overexpression also has another effect: while cells grown under limiting conditions, such as serum starvation, are normally blocked at G0 or G1 in the cell cycle, cells that overexpress *c-myc* undergo apoptosis under these conditions. Overexpression of *bcl-2* can rescue these cells from premature death^{7,8}. Tumor cells *in vivo* must frequently be in situations where growth factors are at low concentration, for example, in poorly vascularized areas or near necrotic portions of tumors. This may explain why alterations at the *bcl-2* locus often accompany *c-myc* overexpression in lymphomas. It is likely that other combinations of oncogenes act in a similar way to alter the complex balance between cell division and cell death that determines whether a subpopulation of tumor cells will expand.

One exception to the requirement for two separate oncogenes to transform primary cells is informative.




FIG 2

Oncogene synergism *in vivo*. Kinetics of breast tumor occurrence in mice transgenic for the *ras* or *myc* oncogene, and in mice doubly transgenic for *ras* and *myc*. Expression of *ras* and *myc* was under the control of the mouse mammary tumor virus breast-specific promoter. Values for t_{50} , the age by which 50% of mice had developed tumors, are as follows: *myc* transgenics, 325d (n = 50); *ras* transgenics, 168d (n = 52); *myc + ras* transgenics, 46d (n = 9). Reproduced, with permission, from Ref. 13.

When oncogenes are transfected together with genes encoding drug resistance, only cells that have incorporated the resistance markers can form colonies in the presence of drugs. Under these conditions, a single oncogene is sufficient for neoplastic transformation of the selected colonies⁹. It seems that in normal cells, cell-cell contact inhibits the growth of cells expressing a single oncogene, but if this cell contact inhibition is removed (by killing normal cells with a drug) one constraint on abnormal growth is removed and full transformation ensues¹⁰. Thus, the cellular environment (as well as the cell type and species) can modulate the number of hits required for tumorigenicity. One would expect, from these observations, that mutations that disrupt cell interactions might play an important role in promoting the growth of some cancers. This expectation has been realized: some mutations seen in human cancers reduce the expression of cell adhesion molecules, and artificial modulation of cell adhesion can promote tumor cell growth and/or invasion¹¹.

Tumors in transgenic animals

Studies using transgenic mice have made an important contribution to our understanding of cancer over the past decade. When an oncogene such as *myc* is transferred to the mouse germ line under the control of a breast-cell specific promoter, the transgenic animals develop breast tumors¹². However, of the thousands of breast tumor stem cells in the mouse, only one or two become neoplastic. This suggests that the presence of a single oncogene is not sufficient for tumorigenesis, even when the gene is expressed at constitutively high levels for long periods. However, doubly transgenic mice, made by breeding *myc* transgenics with mice




FIG 3

A genetic model for colorectal tumorigenesis. Modified from Ref. 4.

transgenic for a second breast-specific oncogene, develop tumors much earlier and more frequently (Fig. 2). Again, two oncogenes are more efficient than one. Even in the doubly transgenic mice, however, the proportion of breast cells that become neoplastic is still small, suggesting that further mutations are required to convert a normal breast epithelial cell into a cancerous one¹³. It will be of interest to determine how many transgenic oncogenes are required to convert all breast epithelial cells to malignancy, independent of additional somatic mutation.

Tumors in humans

Studies of human tumors have added a new dimension to this story. In animals, the tumorigenic process has been analysed primarily in tumors deliberately induced by mutagenic agents or viruses. In humans, dissection of the process has proceeded through the characterization of mutations occurring in sporadic tumors, often involving genes identified by positional cloning approaches. Part of the revolution in cancer research in the 1980s was the discovery that the two approaches converge: the same kinds of genes are mutated in all tumors.

Much of the research on human cancers has centered on tumor suppressor genes. These genes are negative regulators of cellular proliferation and their inactivation by mutation results in the loss of a crucial 'brake' on tumor growth. To date, six presumptive suppressor genes, each mutated in a different spectrum of human cancers, have been identified: the retinoblastoma gene, *RB* (chromosome 13q); the Wilms' tumor gene, *WT1* (11p); the gene deleted in colon carcinoma, *DCC* (18q); the neurofibromatosis type 1 gene, *NF1* (17q); the *p53* gene (17p); and the gene involved in familial adenomatous polyposis coli, *APC* (5q). Several other suppressor genes have been localized to specific chromosomal regions by linkage analysis in kindreds with inherited tumor predisposition syndromes or by the pattern of somatic chromosomal losses in tumors¹⁴. Such genes can be mutationally inactivated in the germ line, resulting in a predisposition to tumors, or, more commonly, undergo somatic mutation, leading to initiation or progression of sporadic tumors.

A good illustration of how the studies of experimental systems and human tumors have converged,

and an example of particular relevance to the multi-hit phenomenon, is provided by human papilloma viruses (HPVs). These viruses have at least two oncogenes (*E6* and *E7*) that can transform appropriate recipient cells in culture. Infection of human cervical cells with these viruses *in vivo* appears to be the first step in the pathway towards cervical cancer¹⁵. Infection may actually represent a double hit, because the *E6* and *E7* proteins bind to, and presumably inactivate, the products of two suppressor genes (the *p53* and *RB* proteins, respectively). Only those HPV subtypes whose *E6* and *E7* proteins bind *RB* and *p53* are associated with cancers in humans^{16,17}. In cervical tumors that are not associated with HPV infection, *p53* (and perhaps *RB*) may be inactivated by mutations, such as deletions, splice-site changes and codon substitutions, rather than by binding to a viral protein¹⁸. Progression of HPV-initiated cells to the fully malignant state requires additional hits in genes not yet identified.

Another example of the interaction between experimental and human tumor research is the characterization of chronic myelogenous leukemia (CML). One of the viruses that causes leukemia in mice carries a transduced and mutated version of a cellular gene, *c-abl*. The mutation results in constitutive activity of the *abl* tyrosine kinase. In CML in humans, the *ABL* gene on chromosome 9 is translocated to a locus on chromosome 22 (Ref. 19). This translocation results in the activation of the *ABL* tyrosine kinase, and is an early (but perhaps not the first²⁰) genetic event in the development of CML. Additional genetic alterations, largely undefined at the molecular level, are required to convert the relatively indolent CML to the more aggressive forms that kill the patient; this is yet another example of the need for multiple hits in cancer evolution.

Numerous other common human tumors, including those of the breast, brain, lung, bladder, bone and colon, have been shown to have mutations at more than one gene. Because colon tumors evolve through well-defined morphological stages, it has been possible to establish the order in which mutations occur in this tumor type (Fig. 3). The development of colorectal tumors appears to be initiated by mutations at the *APC* tumor suppressor gene. These mutations usually cause truncation of the protein. It is not yet clear whether the second hit is a mutation at the remaining *APC* allele,

resulting in the total absence of functional gene product, or a mutation of some other, as yet unidentified, gene. Mutation of *APC* can occur somatically, causing initiation of a single colorectal tumor²¹, or in the germ line, resulting in a predisposition to such tumors^{22,23}. Patients who have a germ-line mutation of *APC* develop thousands of tumors throughout their colon; this is a remarkable demonstration of what can happen when a brake controlling cell growth is lost. Mutation at *APC* leads to the formation of benign adenomas which gradually grow bigger. Mutation of the *RAS* gene often occurs in one of these benign tumor cells, leading to a further clonal expansion. Sequential mutations in the *DCC* and *p53* tumor suppressor genes appear to complete the process, driving waves of clonal expansion that finally result in progression from the benign to the malignant state. No stage of tumorigenesis is static, including the malignant (carcinomatous) stage; additional mutations occur, giving rise to small subpopulations that may not overgrow the entire tumor. These clonal subsets are one of the most difficult challenges in clinical oncology, as they are a reservoir of genetically heterogeneous cells with varying capacities for growth, differentiation and metastasis, and differential sensitivities to drugs, radiation and immune attack.

In all of the human tumors discussed above, mutations in one particular gene appear to precede those in others. Because the oncogenes and tumor suppressor genes so far identified appear to control different cell growth circuits, one might expect that the order in which the circuits are interrupted would be unimportant, and that so long as a sufficient number of critical pathways were disabled, tumor growth would ensue. In fact, although there is some variability in the order of mutations, there is also a clear preference. In CML, colorectal tumors and bladder neoplasias, respectively, mutations at *ABL* (Ref. 19), *APC* (Ref. 21), and a gene on chromosome 9q (Ref. 24) clearly precede other mutations. This suggests that only a subset of genetic pathways can initiate the tumorigenic process in particular cell types and that mutation at some genes confers a selective growth advantage only at later stages in tumor development. Moreover, in most epithelial cells, the neoplastic pathways appear to be guarded by suppressor genes, rather than oncogenes. The reverse may be true in hematopoietic cells, where mutation of an oncogene often appears to be the initiating event in neoplasia. Mutations at *RAS*, although powerful in some situations, appear to have little effect on the neoplastic transformation of epithelial cells in the absence of other critical changes. This explains why mutations of *RAS* in human tumors always occur as a late event that promotes tumor progression, rather than an early event that initiates the process.

Prospects

One of the beauties of genetics as a science is the clear cause and effect relationships that can be inferred, relating genotype to phenotype. The genetics of cancer forces us to re-examine our simple notions of causality, such as those embodied in Koch's postulates; how does one come to grips with words like 'necessary' and 'sufficient' when more than one mutation is required to produce a phenotype and when

that phenotype can be produced by different mutant genes in various combinations? Similar problems arise in the analysis of other complex human diseases, such as those involving autoimmunity, atherosclerosis, hypertension and psychiatric disorders. Perhaps the conceptual lessons derived from the study of cancer will also apply to these other conditions.

On the positive side, it should be emphasized that an appreciation of the complexity and multiplicity of genetic events is the first step towards understanding these common and often lethal diseases. Moreover, multiple mutations provide multiple targets for intervention. Indeed, it has been shown that when a single normal gene or chromosomal region is introduced into a cancer cell with multiple mutations, cell growth and/or invasion can be dramatically inhibited, at least in the test tube²⁵. While it is likely to be some time before we can successfully apply this type of therapy to human cancers *in vivo*, it may eventually be possible to develop drugs that will mimic the effect of normal suppressor genes or interfere with the effect of mutant oncogenes. A highlight of the last decade was the discovery of many of the genes that are responsible for human cancer. The next decade should see the characterization of the biochemical and physiological mechanisms that underlie the action of these genes, facilitating novel approaches to both therapy and prevention.

References

- 1 Miller, D.G. (1980) *Cancer* 46, 1307-1318
- 2 Nowell, P. (1976) *Science* 194, 23-38
- 3 Boice, J.D. and Monson, R.R. (1977) *J. Natl Cancer Inst.* 59, 823-835
- 4 Fearon, E.R. and Vogelstein, B. (1990) *Cell* 61, 757-767
- 5 Knudson, A.G. (1985) *Cancer Res.* 45, 1437-1443
- 6 Weinberg, R.A. (1985) *Science* 230, 770-783
- 7 Bissonette, R.P., Echeverri, F., Mahboubi, A. and Green, D.R. (1992) *Nature* 359, 552-554
- 8 Fanidi, A., Harrington, E.A. and Evan, G.I. (1992) *Nature* 359, 554-556
- 9 Spandidos, D.A. and Wilkie, N.M. (1970) *Nature* 310, 469-474
- 10 Land, H. et al. (1986) *Mol. Cell. Biol.* 6, 1917-1925
- 11 Hedrick, L., Cho, K.R. and Vogelstein, B. (1992) *Trends Cell Biol.* 3, 36-39
- 12 Adams, J.M. and Cory, S. (1991) *Science* 254, 1161-1167
- 13 Sinn, E. et al. (1987) *Cell* 49, 465-475
- 14 Stanbridge, E.J. (1990) *Annu. Rev. Genet.* 24, 615-657
- 15 Zur Hausen, H. (1991) *Science* 254, 1167-1173
- 16 Dyson, N., Howley, P.M., Munger, K. and Harlow, E. (1989) *Science* 243, 934-937
- 17 Werness, B.A., Levine, A.J. and Howley, P.M. (1990) *Science* 248, 76-79
- 18 Crook, T. et al. (1992) *Lancet* 339, 1070-1073
- 19 Epner, D.E. and Koeffler, H.P. (1990) *Ann. Intern. Med.* 113, 3-6
- 20 Raskind, W.H. and Fialkow, P.J. (1987) *Adv. Cancer Res.* 49, 127-167
- 21 Powell, S.M. et al. (1992) *Nature* 359, 235-237
- 22 Nishisho, I. et al. (1991) *Science* 253, 665-669
- 23 Groden, J. et al. (1991) *Cell* 66, 589-600
- 24 Olumi, A.F. et al. (1990) *Cancer Res.* 21, 7081-7083
- 25 Goyette, M.C. et al. (1992) *Mol. Cell. Biol.* 12, 1387-1395

B. VOGELSTEIN AND K.W. KINZLER ARE IN THE JOHNS HOPKINS ONCOLOGY CENTER, BALTIMORE, MD 21231, USA.